Novel peptides and compositions of peptides for the immunotherapy of lancer cancer, including nsclc,

By developing new peptide sequences and variants bound to HLA-I molecules, the problems of large side effects, high cost and poor treatment effects of existing lung cancer treatment methods are solved, and effective immunotherapy in NSCLC and SCLC are achieved. Biomarkers are provided for diagnosis and predicting treatment success.

CN119080881APending Publication Date: 2024-12-06IMMATICS BIOTECHNOLOGIES GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411243812.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-07-07
Filing Date
2018-07-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing lung cancer treatment methods have problems such as high side effects, high cost and poor treatment effect, especially in advanced lung cancer. Traditional chemotherapy can easily lead to drug resistance. Existing immunotherapy methods such as L-BLP25 or MAGEA3 vaccine are used in NSCLC patients. There is no evidence of survival advantages in the disease and lack of effective biomarkers for diagnosis and prediction of therapeutic success.

Method used

A series of novel peptide sequences and their variants are developed, derived from HLA-I molecules in human tumor cells, able to bind to MHC molecules, stimulate anti-tumor immune responses, and used as vaccines or drug components to activate T cells , targeted therapy in combination with antibodies or soluble T cell receptors, is used to stimulate an immune response to lung cancer.

Benefits of technology

Through these novel peptide sequences and variants, it can effectively stimulate the anti-tumor immune response, improve the killing ability of lung cancer cells, reduce side effects, provide potential biomarkers for diagnosis and prediction of treatment success, and expand the treatment plan for NSCLC and SCLC .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention also relates to tumor-associated T cell peptide epitopes, alone or in combination with other tumor-associated peptides (active pharmaceutical ingredients of vaccine complexes that stimulate anti-tumor immune responses or stimulate T cells ex vivo and transfer into patients). Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, may also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapy methods. In particular, the present invention relates to immunotherapy for cancer. The present invention also relates to tumor-associated T cell (CTL) peptide epitopes used alone or in combination with other tumor-associated peptides (active pharmaceutical ingredients of vaccine complexes that stimulate anti-tumor immune responses or stimulate T cells in vitro and transfer to patients). Peptides that bind to major histocompatibility complex (MHC) molecules or peptides of the same class may also be targets for antibodies, soluble T cell receptors and other binding molecules.

[0002] The present invention relates to several novel peptide sequences and variants thereof, which are derived from HLA class I molecules of human tumor cells and can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for developing pharmaceutical / immunologically active compounds and cells. Background of the Invention

[0004] Lung cancer is responsible for most cancer-related deaths in both men and women. Lung cancer is the most common cancer worldwide in terms of both incidence and mortality. In 2012, there were more than 1.8 million new cases (13% of all cancer cases) and 1.6 million deaths from lung cancer (20% of all cancer deaths). Lung cancer is the leading cause of cancer death in men in 87 countries and in women in 26 countries. More than one-third of newly diagnosed cases are in China. The highest mortality rates are in North America, Europe, and East Asia (World Cancer Report, 2014).

[0005] Since 1987, more women have died each year from lung cancer than from breast cancer. From 1991 to 2003, the death rate for men continued to decline, by about 1.9% per year. The death rate for women from lung cancer is leveling off after increasing for several decades. These trends in lung cancer death rates reflect the decline in smoking rates over the past 30 years.

[0006] According to the National Cancer Institute (NCI), an estimated 230,000 new cases of lung cancer and 160,000 deaths from lung cancer were expected in the United States in 2013.

[0007] Previously, small cell lung cancer (SCLC) was distinguished from non-small cell lung cancer (NSCLC), which includes the histological types of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. However, in the past decade, the distinction between adenocarcinoma and squamous cell carcinoma has become increasingly recognized due to major differences in genetics and responses to specific treatments. Therefore, lung cancer has been further classified according to molecular subtypes based on specific genetic alterations that drive and maintain lung tumorigenesis (Travis et al., 2013).

[0008] The prognosis is generally poor. Of all lung cancer patients, 10%-15% survive five years after diagnosis. The poor survival of lung cancer patients is due (at least in part) to the fact that 80% of patients have metastases at the time of diagnosis, and more than half of patients have distant metastases (SEER Stat facts, 2014). At the time of onset, 30-40% of NSCLC cases are at stage IV, and 60% of SCLC cases are at stage IV.

[0009] The 1-year relative survival rate for lung cancer was 35% during 1975-1979, and rose slightly to 44% in 2010, mainly due to improvements in surgical techniques and the use of combination therapy. However, for all stages of lung cancer combined, the 5-year survival rate is only 17%. For cases where the disease is still localized at the time of detection, the survival rate is 54%; however, only 16% of lung cancers are diagnosed at this early stage (SEER Stat facts, 2014).

[0010] Treatment options depend on the type of cancer (small cell lung cancer or non-small cell lung cancer) and stage and may include surgery, radiation therapy, chemotherapy, or targeted biological therapy, such as bevacizumab. and erlotinib . For localized cancers, surgery is usually the treatment of choice. Recent studies have shown that surgery followed by chemotherapy improves survival in early-stage non-small cell lung cancer. Because the disease has usually spread by the time it is discovered, radiation and chemotherapy are often used, sometimes in combination with surgery. Chemotherapy alone or in combination with chemoradiotherapy is the usual treatment of choice for small cell lung cancer; a large proportion of patients achieve remission with this regimen, and in some cases where surgery is performed, the remission is durable (S3-LeitlinieLungenkarzinom, 2011).

[0011] Advanced lung cancer also becomes resistant to conventional chemotherapy. However, recent advances have led to exciting advances in treatment approaches based on histology and genetics. The review level is: Adjuvant chemotherapy trials designed to differentiate between codon 12 and 13 mutations of KRAS and different amino acid substitutions identified by specific mutations in codon 12 (Shepherd et al., 2013).

[0012] In order to expand the treatment options for NSCLC, different immunotherapeutic approaches have been studied or are being studied. Although vaccination with L-BLP25 or MAGEA3 failed to demonstrate a vaccine-mediated survival advantage in NSCLC patients, allogeneic cell-derived vaccines have shown promising results in clinical studies. In addition, further vaccination trials targeting gangliosides, epidermal growth factor receptor, and several other antigens are currently underway. Another strategy to enhance patients' anti-tumor T cell responses includes the use of specific antibodies to block inhibitory T cell receptors or their ligands. Currently, the therapeutic potential of several of the above antibodies (including ipilimumab, nivolumab, pembrolizumab, MPDL3280A, and MEDI-4736) in NSCLC is being evaluated in clinical trials (Reinmuth et al., 2015)

[0013] Given the severe side effects and costs associated with treating cancer, it is desirable to identify factors that can be used to treat cancer in general, and lung cancer (including NSCLC and SCLC) in particular. It is also desirable to identify factors that represent biomarkers for cancer in general and lung cancer (including NSCLC and SCLC) to better diagnose cancer, assess prognosis, and predict treatment success.

[0014] Cancer immunotherapy represents an option for specific targeting of cancer cells while minimizing side effects. Cancer immunotherapy exploits the presence of tumor-associated antigens.

[0015] The current classification of tumor-associated antigens (TAAs) mainly includes the following groups:

[0016] a) Cancer-testis antigens: The first TAAs recognized by T cells belong to this class of antigens, and were initially called cancer-testis (CT) antigens because their members are expressed in histologically distinct human tumors, in normal tissues, only in spermatocytes / spermatogonia of the testis, and occasionally in the placenta. Since testicular cells do not express HLA class I and II molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be considered immunologically tumor-specific. Well-known examples of CT antigens are members of the MAGE family and NY-ESO-1.

[0017] b) Differentiation antigens: Both tumors and normal tissues (the tissue from which the tumor originates) contain TAAs. Most known differentiation antigens are found in melanoma and normal melanocytes. Many of these melanocyte lineage-associated proteins are involved in the biosynthesis of melanin, so these proteins are not tumor-specific, but are still widely used in cancer immunotherapy. Examples include, but are not limited to, tyrosinase and Melan-A / MART-1 for melanoma or PSA for prostate cancer.

[0018] c) Overexpressed TAAs: TAAs encoded by genes that are widely expressed have been detected in histologically distinct tumors as well as in many normal tissues, generally at low expression levels. It is possible that many epitopes processed and potentially presented by normal tissues are below the threshold level for T cell recognition, and their overexpression in tumor cells can trigger an anti-cancer response by breaking previously established tolerance. Typical examples of such TAAs are Her-2 / neu, survivin, telomerase or WT1.

[0019] d) Tumor-specific antigens: These unique TAAs arise from mutations in normal genes (e.g., β-catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and / or progression. Tumor-specific antigens can generally induce a strong immune response without the risk of autoimmune reactions to normal tissues. On the other hand, these TAAs are in most cases only associated with the exact tumor on which the TAA is identified, and are usually not shared between many individual tumors. In the case of proteins containing tumor-specific (associated) isoforms, peptide tumor specificity (or association) may also occur if the peptide is derived from a tumor (associated) exon.

[0020] e) TAAs resulting from aberrant post-translational modifications: These TAAs may be generated from proteins that are neither specific nor overexpressed in tumors, but are still tumor-associated due to post-translational processing that is primarily active on tumors. These TAAs arise from altered glycosylation patterns that result in tumor production of novel epitopes for MUC1 or events such as protein splicing during degradation, which may or may not be tumor-specific.

[0021] f) Oncovirus proteins: These TTAs are viral proteins that play a key role in the carcinogenesis process and because they are foreign (non-human) proteins, they are able to stimulate T cell responses. Examples of such proteins are the human papillomavirus type 16 proteins, E6 and E7, which are expressed in cervical cancer.

[0022] T cell-based immunotherapy targets peptide epitopes derived from tumor-associated or tumor-specific proteins presented by major histocompatibility complex (MHC) molecules. The antigens recognized by tumor-specific T lymphocytes, i.e., their epitopes, can be molecules derived from all types of proteins, such as enzymes, receptors, transcription factors, etc., which are expressed in cells of the corresponding tumor and their expression is usually upregulated compared with homologous unaltered cells.

[0023] There are two types of MHC molecules: MHC class I and MHC class II. MHC class I molecules consist of an alpha heavy chain and beta-2-microglobulin, while MHC class II molecules consist of an alpha and a beta chain. Its three-dimensional structure forms a binding groove for non-covalent interaction with peptides.

[0024] MHC class I molecules are found on most nucleated cells. They present peptides that are mainly endogenous proteins, defective ribosomal products (DRIPs) and peptides generated by cleavage of larger peptides. However, peptides originating from endosomal structures or exogenous sources are also frequently found on MHC class I molecules. This non-classical presentation of class I molecules is referred to in the literature as cross-presentation (Brossart and Bevan, 1997; Rock et al., 1990). MHC class II molecules are mainly found on professional antigen presenting cells (APCs) and mainly present peptides of exogenous or transmembrane proteins that are taken up by APCs during endocytosis and subsequently processed.

[0025] The complex of peptide and MHC class I is recognized by CD8-positive T cells bearing the corresponding T cell receptor (TCR), while the complex of peptide and MHC class II molecule is recognized by CD4-positive helper T cells bearing the corresponding TCR. Therefore, it is a consensus that TCR, peptide and MHC are presented in a 1:1:1 stoichiometry.

[0026] CD4-positive helper T cells play an important role in inducing and maintaining effective responses of CD8-positive cytotoxic T cells. The identification of CD4-positive T cell epitopes derived from tumor-associated antigens (TAAs) is very important for the development of drug products that can induce anti-tumor immune responses (Gnjatic et al., 2003). At the tumor site, T helper cells maintain a cytokine environment that is friendly to cytotoxic T cells (CTLs) (Mortara et al., 2006) and attract effector cells such as CTLs, natural killer (NK) cells, macrophages and granulocytes (Hwang et al., 2007).

[0027] In the absence of inflammation, the expression of MHC class II molecules is mainly limited to cells of the immune system, especially professional antigen presenting cells (APCs), such as monocytes, monocyte-derived cells, macrophages, and dendritic cells. MHC class II molecules have been found to be expressed in tumor cells of cancer patients (Dengjel et al., 2006).

[0028] The elongated (longer) peptides of the present invention can be used as MHC-II class active epitopes. Helper T cells activated by MHC-II class epitopes play an important role in orchestrating the CTL effector functions of anti-tumor immunity. Helper T cell epitopes that trigger TH1 cell responses support the effector functions of CD8 positive killer T cells, including cytotoxic functions that act directly on tumor cells (such tumor cells display tumor-associated peptide / MHC complexes on their surfaces). In this way, tumor-associated T helper cell epitopes used alone or in combination with other tumor-associated peptides can be used as active pharmaceutical ingredients of vaccine compounds that stimulate anti-tumor immune responses.

[0029] Mammalian (e.g. mouse) models have shown that even in the absence of CD8-positive T lymphocytes, CD4-positive T cells can suppress angiogenesis by secreting interferon-γ (IFNγ) and thus be sufficient to suppress tumor expression (Beatty and Paterson, 2001; Mumberg et al., 1999). There is no evidence that CD4 T cells act as direct anti-tumor effectors (Braumuller et al., 2013; Tran et al., 2014).

[0030] Since the constitutive expression of HLA class II molecules is usually limited to immune cells, it was previously considered impossible to isolate class II peptides directly from primary tumors. However, Dengjel et al. successfully identified multiple MHC class II epitopes directly in tumors (WO 2007 / 028574, EP 1 760088B1).

[0031] Since both CD8-dependent and CD4-dependent responses contribute jointly and synergistically to antitumor effects, identifying and characterizing tumor-associated antigens recognized by CD8+ T cells (ligands: MHC class I molecules + peptide epitopes) or CD4-positive T helper cells (ligands: MHC class II molecules) is very important for the development of tumor vaccines.

[0032] For an MHC class I peptide to trigger (elicit) a cellular immune response, it must also bind to an MHC molecule. This process depends on the allele of the MHC molecule as well as the specific polymorphism of the peptide's amino acid sequence. MHC class I-binding peptides are typically 8-12 amino acid residues in length and usually contain two conserved residues ("anchors") in their sequence that interact with the corresponding binding groove of the MHC molecule. In this way, each MHC allele has a "binding motif" that determines which peptides can specifically bind to the binding groove.

[0033] In the MHC class I-dependent immune response, peptides must not only bind to certain MHC class I molecules expressed by tumor cells, but they must then be recognized by specific T cell receptors (TCRs) carried by T cells.

[0034] For proteins that are recognized by T lymphocytes as tumor-specific antigens or associated antigens and used for treatment, some conditions must be met. The antigen should be mainly expressed by tumor cells, not by normal healthy tissues, or the expression amount is relatively small. In a preferred embodiment, the peptide should be over-presented in tumor cells compared with normal healthy tissues. More preferably, the corresponding antigen not only appears in a tumor, but also has a high concentration (i.e., the number of copies of the corresponding peptide per cell). Tumor-specific antigens and tumor-associated antigens are often derived from proteins that are directly involved in the transformation of normal cells into tumor cells due to their functions in cell cycle control or apoptosis inhibition. In addition, the downstream targets of these proteins that directly lead to transformation events may be upregulated and may therefore be indirectly related to tumors. These indirect tumor-associated antigens may also be targets for vaccination methods (Singh-Jasuja et al., 2004). It is crucial that the epitope is present in the antigen amino acid sequence to ensure that such peptides from tumor-associated antigens ("immunogenic peptides") can lead to in vitro or in vivo T cell responses.

[0035] Basically, any peptide that can bind to an MHC molecule can potentially serve as a T cell epitope. The prerequisite for inducing a T cell response in vitro or in vivo is the presence of T cells with the corresponding TCR and the absence of immune tolerance to this specific epitope.

[0036] Therefore, TAAs are the starting point for the development of T cell-based therapies (including but not limited to tumor vaccines). Methods for identifying and characterizing TAAs are usually based on the use of T cells from patients or healthy subjects, or on the generation of differential transcriptional properties or differential expression patterns between tumor and normal tissue peptides. However, the identification of genes that are overexpressed or selectively expressed in tumor tissues or human tumor cell lines does not provide accurate information for the use of antigens transcribed by these genes in immunotherapy. This is because T cells with corresponding TCRs must be present and immune tolerance to this specific epitope must be absent or at a minimal level, so only a part of the epitopes of these antigens are suitable for this application. Therefore, in a very preferred embodiment of the present invention, it is very important to select only those over-presented or selectively presented peptides for which functional and / or proliferative T cells can be found. Such functional T cells are defined as T cells that can be clonally expanded and can perform effector functions ("effector T cells") after stimulation with specific antigens.

[0037] In case of peptide-MHC targeting via specific TCRs (e.g. soluble TCRs) and antibodies or other binding molecules (scaffolds) according to the invention, the immunogenicity of the underlying peptide is secondary. In these cases, presentation is the determining factor.

[0038] Introduction of the invention

[0039] In the first aspect of the present invention, the present invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 489, or a variant sequence of the sequence that is at least 77%, preferably at least 88% homologous (preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 489 (wherein the variant binds to MHC and / or induces T cells to cross-react with the peptide), or a pharmaceutically acceptable salt thereof (wherein the peptide is not the potential full-length polypeptide).

[0040] The present invention further relates to a peptide of the present invention, comprising a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 489, or a variant thereof having at least 77%, preferably at least 88% homology (preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 489, wherein the total length of the peptide or its variant is 8 to 100, preferably 8 to 30, most preferably 8 to 14 amino acids.

[0041] The following table shows the peptides according to the present invention, their respective SEQ ID NOs, and possible source (potential) genes of these peptides. In Table 1, peptides containing SEQ ID NO: 1 to SEQ ID NO: 83 bind to HLA-A*24, peptides containing SEQ ID NO: 84 to SEQ ID NO: 133 bind to HLA-A*02, peptides containing SEQ ID NO: 134 to SEQ ID NO: 201 bind to HLA-A*01, peptides containing SEQ ID NO: 202 to SEQ ID NO: 219 bind to HLA-A*03, peptides containing SEQ ID NO: 220 to SEQ ID NO: 295 bind to HLA-B*07 peptides, peptides containing SEQ ID NO: 296 to SEQ ID NO: 318 bind to HLA-B*08, and peptides containing SEQ ID NO: 319 to SEQ ID NO: 374 bind to HLA-B*44. The peptides in Table 2 were previously disclosed in large lists as a result of high throughput screening with a high error rate or calculated using an algorithm, but have not been previously associated with cancer. In Table 2, peptides containing SEQ ID NO: 375 to SEQ ID NO: 387 bind to HLA-A*24, peptides containing SEQ ID NO: 388 to SEQ ID NO: 393 bind to HLA-A*02, peptides containing SEQ ID NO: 394 to SEQ ID NO: 452 bind to HLA-A*01, peptides containing SEQ ID NO: 453 to SEQ ID NO: 458 bind to HLA-A*03, peptides containing SEQ ID NO: 459 to SEQ ID NO: 475 bind to HLA-B*07 peptides, and peptides containing SEQ ID NO: 476 bind to HLA-B*44. The peptides in Table 3 are other peptides that can be used in combination with other peptides of the present invention. In Table 3, peptides containing SEQ ID NO: 490 to SEQ ID NO: 508 bind to HLA-A*24, peptides containing SEQ ID NO: 509 to SEQ ID NO: 528 bind to HLA-A*02, peptides containing SEQ ID NO: 529 to SEQ ID NO: 530 bind to HLA-B*07, and peptides containing SEQ ID NO: 531 bind to HLA-B*44.

[0042] Table 1: Peptides of the invention.

[0043]

[0044]

[0045]

[0046]

[0047]

[0048]

[0049]

[0050]

[0051]

[0052]

[0053]

[0054] Table 2: Other peptides of the invention with no previous known association with cancer.

[0055]

[0056]

[0057]

[0058]

[0059] Table 3: Peptides of the invention useful, for example, in personalized cancer therapy.

[0060]

[0061]

[0062] Furthermore, the present invention generally also relates to peptides according to the invention for use in the treatment of proliferative diseases, for example, acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, bladder cancer, uterine cancer.

[0063] Particularly preferred are peptides of the present invention (alone or in combination) selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 489. More preferred are peptides (alone or in combination) selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 374 (see Table 1) and used for immunotherapy of lung cancer (including NSCLC and SCLC), acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, bladder cancer, uterine cancer, preferably lung cancer (including NSCLC and SCLC).

[0064] In addition, another aspect of the present invention relates to the use of the peptides according to the present invention - preferably in combination for the treatment of a proliferative disease selected from the group consisting of lung cancer (including NSCLC and SCLC), acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, bladder cancer, and uterine cancer.

[0065] The present invention also relates to the peptides of the present invention, which have the ability to bind to major histocompatibility complex (MHC) class I or MHC class II molecules in an elongated form, for example of varying length.

[0066] The present invention further relates to the peptides of the present invention, wherein said peptide (each peptide) consists of or essentially consists of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 489.

[0067] The present invention further relates to the peptides of the present invention, wherein the peptides are modified and / or comprise non-peptide bonds.

[0068] The present invention further relates to the peptides of the present invention, wherein the peptides are part of a fusion protein, in particular fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or to an antibody (e.g. a dendritic cell-specific antibody) or a sequence of an antibody.

[0069] The present invention further relates to a nucleic acid encoding the peptide of the present invention. The present invention further relates to a nucleic acid of the present invention, which is DNA, cDNA, PNA, RNA, or a combination thereof.

[0070] The present invention further relates to an expression vector capable of expressing and / or expressing the nucleic acid of the present invention.

[0071] The present invention further relates to a peptide of the present invention, a nucleic acid of the present invention or a pharmaceutical expression vector of the present invention for treating a disease, in particular for treating cancer.

[0072] The present invention further relates to antibodies specific for the peptides of the present invention or complexes of the peptides of the present invention (containing MHC) and methods for producing these antibodies.

[0073] The present invention further relates to the T cell receptors (TCRs) of the present invention, in particular soluble TCRs (sTCRs) and cloned TCRs processed into autologous or allogeneic T cells, as well as methods for producing these TCRs and methods for producing NK cells carrying the TCRs or cross-reacting with the TCRs.

[0074] Antibodies and TCRs are further embodiments of the immunotherapeutic uses of peptides according to the current invention.

[0075] The present invention further relates to a host cell comprising the nucleic acid of the present invention or the aforementioned expression vector. The present invention further relates to the host cell of the present invention, which is an antigen presenting cell, preferably a dendritic cell.

[0076] The present invention further relates to a method of formulating a peptide of the present invention, said method comprising culturing the host cell of the present invention and isolating the peptide from said host cell or its culture medium.

[0077] The present invention further relates to the method of the present invention, wherein the antigen is carried onto the class I or II MHC molecules expressed on the surface of suitable antigen-presenting cells or artificial antigen-presenting cells by binding to a sufficient amount of antigen-containing antigen-presenting cells.

[0078] The present invention further relates to the method of the present invention, wherein the antigen presenting cell consists of an expression vector capable of expressing the peptide comprising SEQ ID NO.1 to SEQ ID NO.489, preferably comprising SEQ ID No.1 to SEQ ID No.374, or a variant amino acid sequence.

[0079] The present invention further relates to activated T cells produced by the method of the present invention, wherein the T cells selectively recognize a cell that expresses a polypeptide comprising an amino acid sequence of the present invention.

[0080] The present invention further relates to a method for killing target cells of a patient, wherein the target cells of the patient abnormally express a polypeptide comprising any amino acid sequence of the present invention, the method comprising administering to the patient an effective amount of T cells produced by the method of the present invention.

[0081] The present invention further relates to the use of any of the peptides, the nucleic acids of the present invention, the expression vectors of the present invention, the cells of the present invention, the activated T lymphocytes of the present invention, the T cell receptors or antibodies or other peptide- and / or peptide-MHC binding molecules as a medicament or for the manufacture of a medicament. The medicament preferably has anticancer activity.

[0082] Preferably, the agent is a cell therapy drug, vaccine or protein based on soluble TCR or antibody.

[0083] The present invention further relates to the use of the peptide according to the present invention, wherein the cancer cells are lung cancer (including NSCLC and SCLC), acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, bladder cancer, uterine cancer, preferably lung cancer (including NSCLC and SCLC) cells.

[0084] The present invention further relates to a biomarker based on the peptides of the present invention, herein referred to as a "target", which can be used to diagnose cancer, preferably lung cancer (including NSCLC and SCLC). The marker can be over-presented by the peptide itself or over-expressed by the corresponding gene. The marker can also be used to predict the likelihood of success of treatment, preferably immunotherapy, most preferably immunotherapy targeting the same target recognized by the biomarker. For example, antibodies or soluble TCRs can be used to stain tumor sections to detect the presence of the relevant peptide complexed with MHC.

[0085] Alternatively, the antibody may have further effector functions, such as an immunostimulatory domain or a toxin.

[0086] The present invention also relates to the use of these novel targets in cancer treatment.

[0087] Whether an immune response can be stimulated depends on the presence of antigens that are considered foreign by the host immune system. The discovery of tumor-associated antigens has raised the possibility of using the host immune system to intervene in tumor growth. Currently, various mechanisms of using the humoral and cellular aspects of the immune system are being explored for cancer immunotherapy.

[0088] Specific elements of the cellular immune response can specifically recognize and destroy tumor cells. T-cells isolated from tumor-infiltrating cell populations or peripheral blood have shown that these cells play an important role in the natural immune defense against cancer. An important role in this response is played by CD8-positive T cells, which recognize class I molecules contained in peptides carried by the major histocompatibility complex (MHC) of usually 8 to 10 amino acid residues derived from proteins or defective ribosomal products (DRIPs) located in the cytoplasm. Human MHC molecules are also called human leukocyte-antigens (HLA).

[0089] Unless otherwise stated, all terms used herein are defined below.

[0090] The term "T cell response" refers to the specific proliferation and activation of effector functions induced by a peptide in vitro or in vivo. For MHC class I restricted cytotoxic T cells, the effector function may be lysis of peptide-pulsed, peptide precursor-pulsed or native peptide-presenting target cells, secretion of cytokines, preferably peptide-induced interferon-γ, TNF-α or IL-2, secretion of effector molecules, preferably peptide-induced granzymes or perforins, or degranulation.

[0091] As used herein, the term "peptide" refers to a series of amino acid residues, usually linked by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. These peptides are preferably 9 amino acids in length, but can be as short as 8 amino acids in length, as long as 10, 11, or 12 amino acids or longer, and in the case of MHC class II peptides (elongated variants of the peptides of the present invention), can be as long as 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length or longer.

[0092] In addition, the term "peptide" shall include salts of a series of amino acid residues, usually linked by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. Preferably, the salt is a pharmaceutically acceptable salt of the peptide, for example, a chloride or acetate (trifluoroacetate) salt. It must be noted that the salts of the peptides of the present invention are substantially different from the peptides in their in vivo state, since they are not salts in vivo.

[0093] The term "peptide" shall also include "oligopeptide". The term "oligopeptide" as used herein refers to a series of amino acid residues, usually connected by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. The length of the oligopeptide is not critical to the present invention, as long as the correct epitope is maintained in the oligopeptide. Typically, the oligopeptide is less than about 30 amino acid residues in length and is longer than about 15 amino acids.

[0094] The term "polypeptide" refers to a series of amino acid residues, usually connected by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. The length of the polypeptide is not critical to the present invention as long as the correct epitope is maintained. In contrast to the terms peptide or oligopeptide, the term "polypeptide" refers to molecules containing more than about 30 amino acid residues.

[0095] A peptide, oligopeptide, protein or nucleotide encoding the molecule is "immunogenic" (and therefore an "immunogen" in the present invention) if it is able to induce an immune response. In the context of the present invention, a more specific definition of immunogenicity is the ability to induce a T cell response. Thus, an "immunogen" is a molecule capable of inducing an immune response, and in the context of the present invention, a molecule capable of inducing a T cell response. In another aspect, the immunogen may be a peptide, a complex of a peptide with MHC, and / or a protein for enhancing specific antibody or TCR resistance.

[0096] A class I T cell "epitope" requires a short peptide that binds to the MHC class I receptor, forming a ternary complex (MHC class I alpha chain, beta-2-microglobulin, and peptide) that can be recognized by a T cell bearing a matching T cell receptor bound to the MHC / peptide complex with appropriate affinity. The typical length of peptides bound to MHC class I molecules is 8-14 amino acids, with 9 amino acids being the most typical.

[0097] In humans, there are three different loci encoding MHC class I molecules (human MHC molecules are also designated human leukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02, and HLA-B*07 are examples of different MHC class I alleles that can be expressed from these loci.

[0098] Table 4: Expression frequency F of HLA-A*02, HLA-A*01, HLA-A*03, HLA-A*24, HLA-B*07, HLA-B*08 and HLA-B*44 serotypes. The haplotype frequency Gf is derived from a study that used HLA typing data from more than 6.5 million volunteer donors in the United States (Gragert et al., 2013). The haplotype frequency is the frequency of a unique allele gene on an individual chromosome. Due to the diploid chromosome set in mammalian cells, the genotype of this allele gene has a high frequency of occurrence and can be calculated using the Hardy-Weinberg law (F=1(1-Gf)2).

[0099]

[0100]

[0101] The peptides of the invention, when incorporated into the vaccines of the invention as described herein, preferably bind to A*02, A*01, A*03, A*24, B*07, B*08 or B*44. The vaccine may also include pan-binding MHC class II peptides. Thus, the vaccines of the invention can be used to treat cancer in patients who are A*02, A*01, A*03, A*24, B*07, B*08 or B*44 positive, but do not necessarily require selection of MHC class II allotypes due to the broad binding properties of these peptides.

[0102] If the A*02 peptide of the present invention is combined with a peptide that binds to another allele, such as A*24, a higher proportion of the patient population can be treated compared to the MHC class I allele alone. Although in most populations, less than 50% of patients can be treated with a single allele, a vaccine containing HLA-A*24 and HLA-A*02 epitopes according to the present invention can treat at least 60% of patients in any relevant population. Specifically, the following proportions of patients in each region have a positive effect on at least one of these alleles: 61% in the United States, 62% in Western Europe, 75% in China, 77% in South Korea, and 86% in Japan (calculated according to www.allelefrequencies.net).

[0103] Table 5: HLA allele coverage in the European white population (calculated according to the method described in (Gragert et al., 2013)).

[0104]

[0105] In a preferred embodiment, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides.

[0106] The nucleotide sequence encoding a specific peptide, oligopeptide or polypeptide may be a natural nucleotide sequence or a synthetic nucleotide sequence. In general, the DNA fragment encoding the peptide, polypeptide and protein of the present invention is composed of a cDNA fragment and a short oligonucleotide linker, or a series of oligonucleotides, to provide a synthetic gene that can be expressed in a recombinant transcription unit containing regulatory elements derived from a microorganism or a viral operon.

[0107] As used herein, the term "nucleotide encoding a peptide" refers to a nucleotide sequence encoding a peptide, wherein the peptide includes artificial (man-made) start and stop codons compatible with the biological system in which the sequence will be expressed by dendritic cells or another cell system used to generate TCRs.

[0108] The nucleic acid sequences mentioned herein include both single-stranded nucleic acids and double-stranded nucleic acids. Therefore, unless otherwise indicated herein, for example, for DNA, a specific sequence is a single-stranded DNA of the sequence, a duplex (double-stranded DNA) of the sequence and its complementary sequence, and the complementary sequence of the sequence.

[0109] The term "coding region" refers to that portion of a gene that naturally or normally encodes the expression product of the gene in its natural genomic environment, ie, the region that encodes the native expression product of the gene in vivo.

[0110] The coding region can be derived from a non-mutated ("normal") gene, a mutant gene, or an abnormal gene, and can even be derived from a DNA sequence that can be synthesized entirely in the laboratory using DNA synthesis methods well known in the art.

[0111] The term "expression product" refers to a polypeptide or protein which is the product of translation of a gene and any nucleic acid sequence encoding the equivalent resulting from the degeneration of the genetic code and thereby encoding the same amino acids.

[0112] The term "fragment", when referring to a coding sequence, means a portion of DNA including a non-complete coding region, the expression product of which has substantially the same biological function or activity as the expression product of the complete coding region.

[0113] The term "DNA fragment" refers to a DNA polymer, either in the form of an individual fragment or as a component of a larger DNA structure, obtained from DNA that has been isolated at least once in a substantially pure form, i.e., free of contaminating endogenous materials, and in quantities or concentrations that allow for the identification, manipulation, and recovery of the fragment and its component nucleotide sequences using standard biochemical methods, such as the use of cloning vectors. Such fragments are present in the form of open reading frames (not interrupted by internal untranslated sequences) or introns (commonly present in eukaryotic genes). Untranslated DNA sequences may be present downstream of the open reading frame, where they do not interfere with the manipulation or expression of the coding region.

[0114] The term "primer" refers to a short nucleic acid sequence that pairs with a DNA strand and provides a free 3'-OH terminus at which DNA polymerase begins to synthesize a DNA strand.

[0115] The term "promoter" refers to a region of DNA that participates in the binding of RNA polymerase and thereby initiates transcription.

[0116] The term "isolated" means that a material is removed from its original environment (e.g., its natural environment if naturally occurring). For example, a native nucleotide or polypeptide in a living animal is not isolated, but a nucleotide or polypeptide separated from some or all of the coexisting materials in the natural system is isolated. Such polynucleotides may be part of a vector and / or such polynucleotides and polypeptides may be part of a composition and still be isolated because the vector or composition is not part of its natural environment.

[0117] The polynucleotides and recombinant or immunogenic polypeptides disclosed in the present invention may also exist in a "purified" form. The term "purified" does not require absolute purity; it is only a relative definition and can include highly purified or partially purified preparations, and these terms are understood by technicians in the relevant fields. For example, various clones isolated from a cDNA library that has been purified to electrophoretic homogeneity by traditional methods. It is explicitly considered that the starting material or natural substance is purified by at least one order of magnitude, preferably two or three orders of magnitude, and more preferably four or five orders of magnitude. In addition, it is explicitly contemplated that the purity of the polypeptide is preferably 99.999%, or at least 99.99% or 99.9%; even preferably 99% or more by weight.

[0118] The nucleic acid and polypeptide expression products disclosed in accordance with the present invention, as well as expression vectors comprising such nucleic acids and / or polypeptides, may be present in a "concentrated form". As used herein, the term "concentrated" refers to a material having a concentration of at least about 2, 5, 10, 100 or 1000 times its natural concentration, advantageously 0.01% by weight, preferably at least 0.1%. Concentrated preparations of about 0.5%, 1%, 5%, 10% and 20% by weight are also expressly contemplated. The sequences, configurations, vectors, clones and other materials comprising the present invention may advantageously be present in a concentrated or isolated form. The term "active fragment" refers to a fragment that produces an immune response (i.e., has immunogenic activity), generally a fragment of a peptide, polypeptide or nucleic acid sequence, whether administered alone or optionally with a suitable adjuvant or in a carrier to an animal, such as a mammal, for example a rabbit or mouse, including a human; the immune response takes the form of stimulating a T cell response in the recipient animal (e.g., a human). Alternatively, the "active fragment" may also be used to induce a T cell response in vitro.

[0119] As used herein, the terms "portion", "segment" and "fragment" when used in relation to polypeptides refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide is treated with any endopeptidase (such as trypsin or chymotrypsin), the oligopeptides obtained by the treatment will represent a portion, segment or fragment of the starting polypeptide. When used in relation to polynucleotides, these terms refer to the products produced by treating the polynucleotide with any endonuclease.

[0120] According to the present invention, the term "percent identity" or "percent equivalence", if referring to a sequence, means that the sequence to be compared ("the compared sequence") is compared with the sequence or sequence of the claim ("the reference sequence") after alignment. The percent identity is then calculated according to the following formula: Percent identity = 100[1-(C / R)]

[0121] Where C is the number of differences between the reference sequence and the compared sequence over the alignment length between the reference sequence and the compared sequence,

[0122] (i) Each base or amino acid sequence in the reference sequence has no corresponding base or amino acid in the compared sequence;

[0123] (ii) each gap in the reference sequence, and

[0124] (iii) each base or amino acid in the reference sequence that differs from that base or amino acid in the compared sequence constitutes a difference; and

[0125] (iiii) Alignment must start at the first position of the alignment sequence;

[0126] And R is the number of bases or amino acids in the reference sequence over the length of the alignment between the reference sequence and the compared sequence, with any gaps in the reference sequence also counted as one base or amino acid.

[0127] If there is an alignment between the "compared sequence" and the "reference sequence" where the percent identity calculated as above is approximately equal to or greater than the specified minimum percent identity, then the compared sequence has the specified minimum percent identity to the reference sequence, although there may be alignments where the percent identity calculated as above in this document is lower than the specified percent identity.

[0128] Therefore, as described above, the present invention provides a peptide comprising a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 489, or a variant thereof having 88% homology with SEQ ID NO: 1 to SEQ ID NO: 489, or a variant thereof inducing T cell cross-reaction with the peptide. The peptide of the present invention has the ability to bind to a major histocompatibility complex (MHC) class I or a class II molecule of an elongated version of the peptide.

[0129] In the present invention, the term "homology" refers to the degree of identity between two amino acid sequences (see the percentage of identity above, such as peptide or polypeptide sequences. The "homology" mentioned above is determined by aligning the two sequences adjusted under ideal conditions with the sequences to be compared. Such sequence homology can be calculated by creating an alignment using algorithms such as ClustalW. It can also be used using general sequence analysis software, more specifically Vector NTI, GENETYX or other tools provided by public databases.

[0130] One skilled in the art can assess whether T cells induced by a particular peptide variant can cross-react with the peptide itself (Appay et al., 2006; Colombetti et al., 2006; Fong et al., 2001; Zaremba et al., 1997).

[0131] By "variant" of a given amino acid sequence, the inventors mean that the side chains of one or two amino acid residues, etc., are altered by substitution with the side chains of another naturally occurring amino acid residue or other side chains, such that the peptide is still able to bind to an HLA molecule in substantially the same manner as a peptide comprising the given amino acid sequence (consisting of SEQ ID NO: 1 to SEQ ID NO: 489). For example, a peptide may be modified so as to at least maintain (if not improve) its ability to interact with and bind to the binding groove of a suitable MHC molecule, such as HLA-A*02 or -DR, and at least maintain (if not improve) its ability to bind to the TCR of activated T cells.

[0132] Subsequently, these T cells can cross-react with cells and kill cells that express polypeptides (including the natural amino acid sequence of the homologous peptide defined in the present invention). As described in the scientific literature and databases (Rammensee et al., 1999; Godkin et al., 1997), certain positions of HLA-A binding peptides are usually anchor residues that can form a core sequence that is compatible with the binding motif of the HLA binding groove, which is defined by the polarity, electrophysical, hydrophobicity and spatial properties of the polypeptide chains that constitute the binding groove. Therefore, those skilled in the art can modify the amino acid sequences set forth in SEQ ID No: 1 to SEQ ID NO: 489 by maintaining the known anchor residues, and can determine whether these variants retain the ability to bind to MHC class I or II molecules. The variants of the present invention retain the ability to bind to the TCR of activated T cells, and subsequently, these T cells can cross-react with cells expressing a polypeptide including the natural amino acid sequence of the homologous peptide defined in the present invention and kill these cells.

[0133] If not otherwise stated, the original (unmodified) peptides disclosed herein may be modified by replacing one or more residues at different (possibly selective) sites within the peptide chain. Preferably, these substitutions are located at the termini of the amino acid chain. The substitution may be conservative, for example, where one amino acid is replaced by another amino acid of similar structure and characteristics, such as where one hydrophobic amino acid is replaced by another hydrophobic amino acid. More conservative substitutions are substitutions between amino acids of the same or similar size and chemical properties, for example, leucine is replaced by isoleucine. In studies of sequence variation in natural homologous protein families, substitutions of certain amino acids are often more tolerated than others, and these amino acids often show similarities with the original amino acids in size, charge, polarity and hydrophobicity, which is the basis for determining "conservative substitutions".

[0134] In this article, conservative substitutions are defined as exchanges within one of the following five groups: Group 1 small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2 polar, negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3 polar, positively charged residues (His, Arg, Lys); Group 4 large aliphatic nonpolar residues (Met, Leu, Ile, Val, Cys) and Group 5 large aromatic residues (Phe, Tyr, Trp).

[0135] Less conservative substitutions may involve the replacement of one amino acid with another of similar characteristics but different in size, such as the replacement of an alanine with an isoleucine residue. Highly non-conservative substitutions may involve the replacement of an acidic amino acid with another with polar or even basic properties. However, such "radical" substitutions should not be dismissed as ineffective, as chemistry is not entirely predictable and radical substitutions may bring about unforeseen effects that could not be foreseen in their simple chemistry.

[0136] Of course, such substitutions may involve other structures besides common L-amino acids. Thus, D-amino acids may be substituted with common L-amino acids in the antigenic peptides of the present invention, and still be within the scope of the present disclosure. In addition, non-standard amino acids (i.e., in addition to common natural proteinogenic amino acids) may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.

[0137] If substitutions at more than one position are found to result in an antigenic activity of the peptide substantially equal to or greater than the value defined below, combinations of these substitutions are tested to determine whether the combined substitutions produce an additive or synergistic effect on the antigenicity of the peptide. No more than 4 positions may be substituted simultaneously within the peptide.

[0138] A peptide consisting essentially of the amino acid sequence as defined herein may have one or two non-anchor amino acids (see below regarding anchor motifs) exchanged, without the situation being such that the ability to bind to human major histocompatibility complex (MHC) class I or II molecules is substantially altered or adversely affected compared to the unmodified peptide. In another embodiment, in a peptide consisting essentially of the amino acid sequence as defined herein, one or two amino acids may be exchanged with their conservative exchange partners (see below), without the situation being such that the ability to bind to human major histocompatibility complex (MHC) class I or II molecules is substantially altered or adversely affected compared to the unmodified peptide.

[0139] These amino acid residues that do not substantially interact with T cell receptors can be modified by substituting other amino acids that have little effect on T cell response and do not hinder binding to relevant MHC. Therefore, except for specific limiting conditions, the peptide of the present invention may be any peptide (the term used by the inventors includes oligopeptides or polypeptides) comprising a given amino acid sequence or a portion or variant thereof.

[0140] Table 6: Variants and motifs of peptides according to SEQ ID NO: 4, 13, 90.93, 138, 171, 202, 204, 224, 294, 306, 316, 322 and 327

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152] Longer (elongated) peptides may also be suitable. MHC class I epitopes (usually 8 to 11 amino acids in length) may be produced by processing of the peptide from a longer peptide or protein containing the actual epitope. The residues flanking the actual epitope are preferably residues that do not substantially affect the protein cleavage required to expose the actual epitope during processing.

[0153] The peptides of the present invention can be elongated by up to four amino acids, i.e., 1, 2, 3 or 4 amino acids, and can be added to either end in any combination between 4:0 and 0:4. The elongation combinations of the present invention can be seen in Table 7.

[0154] Table 7: Elongated combinations of peptides of the present invention

[0155]

[0156] The stretched / elongated amino acids can be the original sequence peptide of the protein or any other amino acids. Elongation can be used to enhance the stability or solubility of the peptide.

[0157] Therefore, the epitopes described in the present invention may be identical to natural tumor-associated epitopes or tumor-specific epitopes, or may include peptides that differ by no more than four residues from a reference peptide, as long as they have substantially the same antigenic activity.

[0158] In an alternative embodiment, one or both sides of the peptide are extended by more than 4 amino acids, preferably up to a total length of 30 amino acids. This can form an MHC-II class binding peptide. Binding to MHC class II peptides can be tested by methods known in the art.

[0159] Therefore, the present invention provides peptides and variants of MHC class I epitopes, wherein the total length of the peptide or variant is 8 to 100, 9 to 100, 10 to 100, 11 to 100, 12 to 100, preferably 8 to 30, 9 to 30, 10 to 30, 11 to 30, 12 to 30, and most preferably 8 to 14, 9 to 14, 10 to 14, 11 to 14, 12 to 14. The present invention further provides peptides and variants of MHC class I epitopes, wherein the total length of the peptide or antibody is 8, 9, 10, 11, 12, 13 or 14 amino acids, and in the case of elongated class II binding peptides, the length may also be 15, 16, 17, 18, 19, 20, 21 or 22 amino acids.

[0160] Of course, the peptides or variants of the present invention can bind to human major histocompatibility complex (MHC) class I or II molecules. The binding of the peptides or variants to the MHC complex can be tested by methods known in the art.

[0161] Preferably, when the peptide-specific T cells of the present invention are tested in comparison with the substituted peptide, if the substituted peptide has a half-maximal increase in solubility relative to the background peptide, the peptide concentration is no more than about 1 mM, preferably no more than about 1 μM, more preferably no more than about 1 nM, even more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide is recognized by more than one T cell, at least 2, more preferably 3.

[0162] In a particularly preferred embodiment of the present invention, the peptide consists or consists essentially of an amino acid sequence selected according to SEQ ID NO: 1 to SEQ ID NO: 489.

[0163] Essentially consisting of "... " means that the peptide of the present invention, in addition to being composed of any one of SEQ ID NO: 1 to SEQ ID NO: 489 or a variant thereof, also contains amino acids located at other N- and / or C-terminal extensions, which may not necessarily form a peptide that serves as an MHC molecule epitope.

[0164] However, these extended regions play an important role in effectively introducing the peptides of the present invention into cells. In one embodiment of the present invention, the peptide is part of a fusion protein, containing 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, hereinafter referred to as "Ii") from NCBI, GenBank Accession No. X00497. In other fusions, the peptides of the present invention can be fused to the antibodies described herein, or functional parts thereof, in particular to sequences of fused human antibodies, so that the antibodies perform specific targeting, or, for example, enter the dendritic cell-specific antibodies described herein.

[0165] In addition, the peptide or variant can be further modified to improve stability and / or binding to MHC molecules, thereby eliciting a stronger immune response. Such optimization methods of peptide sequences are well known in the art, including, for example, the introduction of trans-peptide bonds and non-peptide bonds.

[0166] In the reverse peptide bond, the amino acid (-CO-NH-) is not attached to its residue, but the peptide bond is reversed. Such retro-inverso peptidomimetics can be prepared by methods known in the art, such as the method described by Meziere et al. (Meziere et al., 1997), which is incorporated herein by reference. This method involves preparing peptidomimetics that contain changes in the backbone (rather than the side chains). Studies by Meziere et al. (Meziere et al., 1997) showed that these analog peptides facilitate MHC binding and helper T cell responses. Retro-inverso peptides with NH-CO bonds instead of CO-NH peptide bonds have greatly improved resistance to hydrolysis.

[0167] Non-peptide bonds are -CH2-NH, -CH2S-, -CH2CH2-, -CH=CH-, -COCH2-, -CH(OH)CH2- and -CH2SO-, etc. U.S. Patent No. 4897445 proposes a non-solid phase synthesis method for non-peptide bonds (-CH2-NH) in polypeptide chains, which involves a polypeptide synthesized according to a standard procedure and a non-peptide bond synthesized through the interaction of an aminoaldehyde and an amino acid containing NaCNBH3.

[0168] Peptides containing the above sequences can be synthesized with other chemical groups at their amino and / or carboxyl termini to improve the stability, bioavailability, and / or affinity of the peptides. For example, hydrophobic groups such as benzyloxycarbonyl, dansyl, or tert-butyloxycarbonyl groups can be added to the amino terminus of the peptide. Similarly, acetyl or 9-fluorenylmethoxycarbonyl groups may be located at the amino terminus of the peptide. In addition, hydrophobic groups, tert-butyloxycarbonyl groups, or amino groups may be added to the carboxyl terminus of the peptide.

[0169] In addition, all peptides of the present invention may be synthesized to change their spatial configuration. For example, the dextrorotatory form of one or more amino acid residues of these peptides may be used, usually not the levorotatory form. Further, at least one amino acid residue of the peptide of the present invention may be substituted by a well-known non-natural amino acid residue. Such changes may help to increase the stability, bioavailability and / or binding effect of the peptide of the present invention.

[0170] Likewise, the peptides or variants of the invention may be chemically modified by reaction of specific amino acids before or after peptide synthesis. Examples of such modifications are well known in the art and are summarized, for example, in R. Lundblad, Chemical Reagents for Protein Modification (3rd ed. CRC Press, 2004) (Lundblad, 2004), which is incorporated herein by reference. Although the methods for chemical modification of amino acids are not limited, they include (but are not limited to) modification by the following methods: acylation, amidination, lysine pyridoylation, reductive alkylation, trinitrophenylation of amino groups with 2,4,6-trinitrobenzenesulfonic acid (TNBS), amino modification of carboxyl groups and sulfhydryl groups by performic acid oxidation of cysteine ​​to cysteic acid, formation of labile derivatives, formation of mixed disulfide compounds with other sulfhydryl compounds, reaction with maleimide, carboxymethylation with iodoacetic acid or iodoacetamide, and methylaminoacylation with cyanate at alkaline pH. In this regard, the skilled person is referred to Chapter 15 of Current Protocols In Protein Science (Eds. Coligan et al. (John Wiley and Sons NY 1995-2000)) (Coligan et al., 1995) for extensive methods related to the chemical modification of proteins.

[0171] In brief, modification of arginyl residues of proteins is often based on the reaction of ortho-dicarbonyl compounds such as benzyl carboxaldehyde, 2,3-butanedione and 1,2-hexanedione to form adducts. Another example is the reaction of methylglyoxal with arginine residues. Cysteine ​​can be modified without concomitant modification of nucleophilic sites such as lysine and histidine. Therefore, there are a large number of reagents for the modification of cysteine. The websites of companies such as Sigma-Aldrich (http: / / www.sigma-aldrich.com) contain information on specific reagents.

[0172] Selective reduction of disulfide bonds in proteins is also common. Disulfide bonds can be formed and oxidized during heat treatment of biopharmaceuticals. Woodward's reagent K can be used to modify specific glutamic acid residues. N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide can be used to form intramolecular crosslinks between lysine residues and glutamic acid residues. For example, diethyl pyrocarbonate is a reagent for modifying histidine residues in proteins. Histidine can also be modified using 4-hydroxy-2-nonenal. Reaction of lysine residues with other α-amino groups, for example, facilitates peptide binding to the surface or crosslinking of proteins / peptides. Lysine is the attachment point for poly(ethylene) glycol and is also the main modification site for protein glycosylation. Methionine residues of proteins can be modified using iodoacetamide, bromoethylamine, chloramine T, etc.

[0173] Tetranitromethane and N-acetylimidazole can be used to modify tyrosine residues. Crosslinking via dityrosine can be accomplished with hydrogen peroxide / copper ions.

[0174] Recent studies on tryptophan modification have used N-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide, or 3-bromo-3-methyl-2-(2-nitrophenylthio)-3H-indole (BPNS-skatole).

[0175] Successful modification of therapeutic proteins and peptides containing polyethylene glycol often results in extended circulation half-lives when cross-linking of proteins with glutaraldehyde, polyethylene glycol diacrylate, and formaldehyde is used to formulate hydrogels. Chemical modification of allergens for immunotherapy is often achieved by carbamidomethylation with potassium cyanate.

[0176] A peptide or variant, wherein the peptide is modified or contains non-peptide bonds, is a preferred embodiment of the present invention.

[0177] Another embodiment of the present invention relates to a non-natural peptide, wherein the peptide consists of or consists essentially of an amino acid sequence according to SEQ ID No: 1 to SEQ ID No: 489 and is synthetically produced (i.e., synthesized) as a pharmaceutically acceptable salt. Methods for synthetically producing peptides are well known in the art. Salts of the peptides of the present invention are substantially different from the peptides in their in vivo state, because these in vivo produced peptides are not salts. The non-natural salt form of the peptide mediates the solubility of the peptide, particularly in the case of a pharmaceutical composition comprising the peptide, for example, a peptide vaccine disclosed herein. In order to effectively provide the peptide to a subject in need of treatment, it is necessary for the peptide to have sufficient, at least substantial, solubility. Preferably, the salt is a pharmaceutically acceptable salt of the peptide. These salts of the present invention include alkali and alkaline earth salts, such as salts of the Hofmeister series, containing anions pO4 3- 、SO4 2- 、CH3COO - , Cl - Br - 、NO3 -、ClO4 - ,I - 、SCN - and cation NH4 + , Rb + , K + 、Na + , Cs + , Li + 、Zn 2+ Mg 2+ , Ca 2+ , Mn 2+ , Cu 2+ and Ba 2+In particular, the salt is selected from (NH4)3PO4, (NH4)2HPO4, (NH4)H2PO4, (NH4)2SO4, NH4CH3COO, NH4Cl, NH4Br, NH4NO3, NH4CIO4, NH4I, NH4SCN, Rb3PO4, Rb2HPO4, RbH2PO4, Rb2SO4, Rb4CH3COO, Rb4Cl, Rb4Br, Rb4NO3, Rb4CIO4, Rb4I, Rb4SCN, K3PO4, K2HP O4, KH2PO4, K2SO4, KCH3COO, KCl, KBr, KNO3, KClO4, KI, KSCN, Na3PO4, Na2HPO4, NaH2PO4, Na2SO4, NaCH3COO, NaC l, NaBr, NaNO3, NaCIO4, NaI, NaSCN, ZnCI2Cs3PO4, Cs2HPO4, CsH2PO4, Cs2SO4, CsCH3COO, CsCl, CsBr, CsNO3, CsCI O4, CsI, CsSCN, Li3PO4, Li2HPO4, LiH2PO4, Li2SO4, LiCH3COO, LiCl, LiBr, LiNO3, LiClO4, LiI, LiSCN, Cu2SO4, M g3(PO4)2, Mg2HPO4, Mg(H2PO4)2, Mg2SO4, Mg(CH3COO)2, MgCl2, MgBr2, Mg(NO3)2, Mg(ClO4)2, MgI2, Mg(SCN)2, Mn Cl2, Ca3(PO4), Ca2HPO4, Ca(H2PO4)2, CaSO4, Ca(CH3COO)2, CaCl2, CaBr2, Ca(NO3)2, Ca(ClO4)2, CaI2, Ca(SCN)2, Ba3(PO4)2, Ba2HPO4, Ba(H2PO4)2, BaSO4, Ba(CH3COO)2, BaCl2, BaBr2, Ba(NO3)2, Ba(ClO4)2, BaI2 and Ba(SCN)2. Particularly preferred are NH3-acetic acid, MgCl2, KH2PO4, Na2SO4, KCl, NaCl and CaCl2, for example chlorides or acetates (trifluoroacetic acid).

[0178] In general, peptides and variants (at least containing peptide linkages between amino acid residues) can be synthesized using the Fmoc-polyamide model of solid phase peptide synthesis as disclosed by Lukas et al. (Lukas et al., 1981) and references cited therein. The fluorenylmethyloxycarbonyl (Fmoc) group provides temporary protection for the N-amino group. This highly alkali-sensitive protecting group is repeatedly cleaved using 20% ​​dimethylpiperidinium in N,N-dimethylformamide. Side chain functions may be protected by their butyl ethers (in the case of serine, threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), tert-butyloxycarbonyl derivatives (in the case of lysine and histidine), trityl derivatives (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulfonyl derivatives (in the case of arginine). Whenever glutamine and asparagine are C-terminal residues, the side chain amino function is protected by a 4,4′-dimethoxydiphenyl group. The solid support is based on polydimethylacrylamide polymer, which is composed of three monomers dimethylacrylamide (backbone monomer), bis(acrylethylenediamine) (crosslinker) and N-acryloylsarcosine methyl ester (functional agent). The peptide-resin linker used is an acid-sensitive 4-hydroxymethylphenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives, except asparagine and glutamine, which are added using a reversed N,N-dicyclohexylcarbodiimide / 1-hydroxybenzotriazole-mediated coupling procedure. All coupling and deprotection reactions are monitored using ninhydrin, nitrobenzenesulfonic acid or isotin test procedures. After the synthesis is completed, the peptide is cleaved from the resin support with the concomitant removal of the side chain protecting groups using a 95% trifluoroacetic acid solution containing 50% scavenger mixture. Commonly used scavenger mixtures include ethanedithiol, phenol, anisole and water, the exact choice depending on the amino acid composition of the synthesized peptide. In addition, it is possible to synthesize peptides using a combination of solid and solution phase methods (see, for example, (Bruckdorfer et al., 2004) and references cited therein).

[0179] Trifluoroacetic acid was removed by evaporation in vacuo followed by titration with diethyl ether loaded with crude peptide. Any scavenger compounds present were removed by a simple extraction procedure which yielded scavenger compound-free peptides after lyophilization of the aqueous phase. Peptide synthesis reagents are generally available from Calbiochem-Novabiochem (Nottingham, UK).

[0180] Purification may be performed by any one or a combination of techniques such as recrystallization, size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography and (usually) reversed-phase high performance liquid chromatography (e.g. using an acetonitrile / water gradient separation).

[0181] Peptide analysis can be performed using thin layer chromatography, electrophoresis, especially capillary electrophoresis, solid phase extraction (CSPE), reversed phase high performance liquid chromatography, amino acid analysis after acid hydrolysis, fast atom bombardment (FAB) mass spectrometry, and MALDI and ESI-Q-TOF mass spectrometry.

[0182] To select over-presented peptides, a presentation plot was calculated that shows the amount of bit presentation in the sample and the variation in replicates. This feature juxtaposes samples of the relevant tumor entity with baseline values ​​of normal tissue samples. Each of the above features can be combined into an over-presentation score by calculating the p-value of the adjusted linear mixed effects model (Pinheiro et al., 2015), thereby adjusting for multiple tests by the false discovery rate (Benjamini and Hochberg, 1995) (see Example 1, Figure 1).

[0183] For identification and relative quantification of HLA ligands by mass spectrometry, HLA molecules from shock-frozen tissue samples were purified and HLA-associated peptides were isolated. The isolated peptides were separated and identified by on-line nano-electrospray-ionization (nanoESI) liquid chromatography-spectroscopy (LC-MS) experiments. The resulting peptide sequences were validated by comparing the fragmentation patterns of natural tumor-associated peptides (TUMAPs) recorded in lung cancer (including NSCLC and SCLC) samples (N=201 samples) with the fragmentation patterns of corresponding synthetic reference peptides of the same sequence. Since these peptides were directly identified as ligands of HLA molecules of primary tumors, these results provide direct evidence for the natural processing and presentation of the identified peptides on primary cancer tissues from 201 patients with lung cancer (including NSCLC and SCLC).

[0184] Discovery pipeline v2.1 (see, e.g., US 2013-0096016, which is hereby incorporated by reference in its entirety) allows for the identification and selection of relevant over-presented peptide vaccine candidates based on direct relative quantification of HLA-restricted peptide levels in cancer or other infected tissues compared to several different non-cancerous tissues and organs. This is achieved by developing a label-free differential quantification method using LC-MS acquired data processed using a proprietary data analysis pipeline, incorporating sequence recognition algorithms, spectral clustering, ion counting, retention time adjustment, charge state convolution, and normalization.

[0185] Presentation levels, including error estimates, were established for each peptide and sample. Peptides that are abundantly presented by tumor tissues as well as peptides that are over-presented in tumor versus non-tumor tissues and organs have been identified.

[0186] HLA peptide complexes from lung cancer (including NSCLC and SCLC) tissue samples were purified, and HLA-associated peptides were separated and analyzed using LC-MS (see Example 1). All TUMAPs included in this application were identified using methods of lung cancer (including NSCLC and SCLC) samples to confirm their presentation on lung cancer (including NSCLC and SCLC).

[0187] TUMAPs identified on multiple lung cancers (including NSCLC and SCLC) and normal tissues were quantified using an ion counting method of label-free LC-MS data. This method assumes that the LC-MS signal area of ​​a peptide is related to its abundance in the sample. All quantified signals of peptides from various LC-MS experiments were normalized on the basis of central tendency, averaged per sample, and merged into a histogram (called a presentation plot). The presentation plot integrates different analytical methods such as protein library searching, spectral clustering, charge state deconvolution (de-charge), and retention time alignment and normalization.

[0188] In addition to over-presenting peptides, mRNA expression of potential genes was also tested. mRNA data were obtained by RNA sequencing analysis of normal tissues and cancer tissues (see Example 2, Figure 2). An additional source of normal tissue data is a database of publicly available RNA expression data from 3000 normal tissue samples (Lonsdale, 2013). Peptides obtained from proteins show high expression of encoding mRNA in cancer tissues, but are very low or absent in important normal tissues, and these peptides are included in the present invention as preferred peptides.

[0189] The present invention provides a method for treating cancer / tumor, preferably lung cancer (including NSCLC and SCLC) that over-presents or exclusively presents the peptides of the present invention. These peptides are directly shown by mass spectrometry to be naturally presented by HLA molecules in human primary lung cancer (including NSCLC and SCLC) samples.

[0190] Compared with normal tissues, many source genes / proteins (also designated as "full-length proteins" or "potential proteins") from which the peptides are derived are highly overexpressed in cancer-the "normal tissues" associated with the present invention are healthy lung cells or other normal tissue cells, which indicates a high degree of association between tumors and these source genes (see Example 2). In addition, these peptides themselves are also over-presented in tumor tissues (the "tumor tissues" associated with the present invention refer to samples from patients with lung cancer (including NSCLC and SCLC)), but not over-presented in normal tissues (see Example 1).

[0191] HLA-bound peptides can be recognized by the immune system, specifically T lymphocytes, which can destroy cells presenting the recognized HLA / peptide complex, such as lung cancer (including NSCLC and SCLC) cells presenting the derived peptides.

[0192] All peptides of the present invention have been shown to have the ability to stimulate T cell responses and are over-presented, and can therefore be used to prepare antibodies and / or TCRs of the present invention, such as soluble TCRs (see Examples 3 and 4). In addition, the peptides can also be used to prepare antibodies and / or TCRs of the present invention, in particular sTCRs, when combined with the corresponding MHC. Each method is well known to the skilled person and can be found in various documents (see also below). Therefore, the peptides of the present invention can be used to generate an immune response in a patient, thereby destroying tumor cells. The patient's immune response can be induced by directly administering the peptide or precursor substance (e.g., extended peptides, proteins, or nucleic acids encoding these peptides) to the patient, preferably in combination with an immunogenicity-enhancing preparation. The immune response derived from the therapeutic vaccine is expected to be highly specific against tumor cells, because the target peptide of the present invention is presented in a low number of copies on normal tissues, preventing the risk of adverse autoimmune reactions against normal cells in patients.

[0193] The present disclosure also relates to a T cell receptor (TCR) comprising an alpha chain and a beta chain ("alpha / beta TCR"). Also provided are peptides of the present invention that can bind to TCRs and antibodies when presented by MHC molecules.

[0194] The present specification also relates to TCR fragments of the present invention that are presented by HLA molecules and are capable of binding to the peptide antigens of the present invention. The term particularly relates to soluble TCR fragments, such as TCRs lacking transmembrane parts and / or constant regions, single-chain TCRs, and fusions thereof with, for example, Ig.

[0195] The present specification also relates to nucleic acids, vectors, and host cells for expressing TCR and peptides of the present specification; and methods of using the same.

[0196] The term "T cell receptor" (abbreviation TCR) refers to a heterodimeric molecule comprising one alpha polypeptide chain (α chain) and one beta polypeptide chain (β chain), wherein the heterodimeric receptor is capable of binding peptide antigens presented by HLA molecules. The term also includes so-called gamma / delta TCRs.

[0197] In one embodiment, the specification provides a method of producing a TCR as described herein, the method comprising culturing a host cell capable of expressing the TCR under conditions suitable for promoting expression of the TCR.

[0198] In another aspect, the present specification relates to a method according to the present specification, wherein the antigen is carried by binding to a sufficient amount of antigen-containing antigen presenting cells and expressed on the surface of a suitable antigen presenting cell or an artificial antigen presenting cell. Class I or II MHC molecules, or the antigen is carried by tetramerization into class I or II MHC tetramers / class I or II MHC complex monomers. The α and β chains of α / βTCR and the γ and δ chains of γ / δTCR are generally regarded as having two "domains" each, namely variable and constant domains. The variable domain is composed of a combination of a variable region (V) and a connecting region (J). The variable domain may also include a leader region (L). The β and δ chains may also include a diversity region (D). The α and β constant domains may also include a C-terminal transmembrane (TM) domain that anchors the α and β chains to the cell membrane.

[0199] With respect to γ / δ TCR, as used herein, the term "TCRγ variable domain" refers to a combination of the TCRγV (TRGV) region without a leader region (L) and the TCRγ (TRGJ) region, and the term TCRγ constant domain refers to the extracellular TRGC region, or a C-terminal truncated TRGC sequence. Similarly, the "TCRδ variable domain" refers to a combination of the TCRδV (TRDV) region without a leader region (L) and the TCRδD / J (TRDD / TRDJ) region, and the term "TCRδ constant domain" refers to the extracellular TRDC region, or a C-terminal truncated TRDC sequence.

[0200] The TCR of the present specification preferably binds to a peptide HLA molecule complex with a binding affinity (KD) of about 100 μM or less, about 50 μM or less, about 25 μM or less, or about 10 μM or less. A more preferred situation is a high affinity TCR with a binding affinity of about 1 μM or less, about 100 nM or less, about 50 nM or less, or about 25 nM or less. Non-limiting examples of preferred binding affinity ranges of the TCR of the present invention include about 1 nM to about 10 nM; about 10 nM to about 20 nM; about 20 nM to about 30 nM; about 30 nM to about 40 nM; about 40 nM to about 50 nM; about 50 nM to about 60 nM; about 60 nM to about 70 nM; about 70 nM to about 80 nM; about 80 nM to about 90 nM; and about 90 nM to about 100 nM.

[0201] As used herein with respect to TCRs of this specification, "specific binding" and its grammatical variations are used to indicate a TCR that has a binding affinity (KD) for a peptide-HLA molecule complex of 100 μM or less.

[0202] The α / β heterodimeric TCRs of the present specification may have introduced disulfide bonds between their constant domains. Preferred TCRs of this type include those having a TRAC constant domain sequence and a TRBC1 or TRBC2 constant domain sequence, unless threonine 48 of TRAC and serine 57 of TRBC 1 or TRBC2 are substituted with cysteine ​​residues that form disulfide bonds between the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence of the TCR.

[0203] With or without the above-mentioned introduced interchain bond, the α / β heterodimeric TCR of the present specification may have a TRAC constant domain sequence and a TRBC 1 or TRBC2 constant domain sequence, and the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence of the TCR may be linked via a native disulfide bond between Cys4 of TRAC exon 2 and Cys4 of TRBC1 or TRBC2 exon 2.

[0204] The TCR of the present specification may include a detectable label selected from the group consisting of a radionuclide, a fluorophore and biotin. The TCR of the present specification may be conjugated to a therapeutically active agent, such as a radionuclide, a chemotherapeutic agent or a toxin.

[0205] In one embodiment, the TCR having at least one mutation in the alpha chain and / or having at least one mutation in the beta chain has modified glycosylation compared to the non-mutated TCR.

[0206] In one embodiment, a TCR comprising at least one mutation in a TCR alpha chain and / or a TCR beta chain has a binding affinity and / or a binding half-life for a peptide HLA molecule complex that is at least twice the binding affinity of a TCR comprising an unmutated TCR alpha chain and / or an unmutated TCR beta chain. Tumor-specific TCR affinity enhancement and its development rely on the existence of a window of optimal TCR affinity. The existence of such a window is based on the observation that HLA-A2 restricted pathogen-specific TCRs are generally about 10 times lower in KD values ​​than HLA-A2 restricted tumor-associated self-antigen-specific TCRs. For TCRs specific to pathogenic genes that are restricted to other alleles compared to tumor-associated self-antigens, KD values ​​may be in slightly different ranges, but there is generally no difference between different alleles in the possibility of creating TCRs. It is now known that although tumor antigens may be immunogenic, because tumors come from an individual's own cells, only mutant proteins or proteins with altered translation processing will be considered foreign substances by the immune system. Antigens that are upregulated or overexpressed (so-called self-antigens) do not necessarily induce a functional immune response against tumors: T cells expressing TCRs that are highly reactive to these antigens are unfavorably selected in the thymus in a process called central tolerance, that is, only cells with low-affinity TCRs for self-antigens remain. Therefore, the affinity of the TCR or variant of the present specification for peptides can be enhanced by methods well known in the art.

[0207] The present specification also relates to a method for identifying and isolating the TCR of the present invention, the method comprising: incubating PBMCs from healthy donors who are currently allele negative with HLA / peptide monomers, incubating PBMCs with tetramer-phycoerythrin (PE) and isolating high-affinity T cells by fluorescence-activated cell sorting (FACS) Calibur method analysis.

[0208] The present specification also relates to a method for identifying and isolating the TCR of the present invention, the method comprising: obtaining transgenic mice containing the entire human TCRαβ gene locus (1.1and 0.7Mb) (whose T cells express diversified human TCRs to compensate for the lack of mouse TCR), immunizing the mice with peptides, incubating PBMCs obtained from the transgenic mice with tetramer-phycoerythrin (PE), and analyzing and isolating high-affinity T cells through fluorescence-activated cell sorting (FACS) Calibur method.

[0209] On the one hand, in order to obtain T cells expressing the TCR of this specification, nucleic acids encoding the TCR-α and / or TCR-β chains of this specification are cloned into expression vectors, such as γ retroviruses or lentiviruses. Recombinant viruses are produced and then tested for function, such as antigen specificity and functional affinity. Then, aliquots of the final product are used to transduce target T cell populations (generally purified from the patient's PBMC) and are launched before entering the patient. On the other hand, in order to obtain T cells expressing the TCR of this specification, TCR RNA is synthesized through techniques known in the art (e.g., in vitro transcription systems). Then, the TCR RNA synthesized in vitro is introduced into primary CD8+T cells obtained from healthy donors by electroporation to re-express tumor-specific TCR-α and / or TCR-β chains.

[0210] To increase expression, the nucleic acid encoding the TCR of the present specification can be operably linked to a strong promoter, such as retroviral long terminal repeats (LTR), cytomegalovirus (CMV), mouse stem cell virus (MSCV) U3, phosphoglycerate kinase (PGK), β-actin, ubiquitin protein and simian virus 40 (SV40) / CD43 composite promoter, elongation factor (EF)-1a and spleen focus forming virus (SFFV) promoter. In a preferred embodiment, the promoter is heterologous to the nucleic acid being expressed. In addition to a strong promoter, the TCR expression cassette of the present specification may contain additional elements that can increase transgene expression, including a central polypurine region (CPPT), which promotes nuclear translocation of lentiviral constructs (Follenzi et al., 2000), and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), which increases transgene expression levels by increasing RNA stability (Zufferey et al., 1999).

[0211] The α and β chains of the TCR of the present invention may be encoded by nucleic acids located on separate vectors, or may be encoded by polynucleotides located on the same vector.

[0212] Achieving high-level TCR surface expression requires the introduction of high-level transcription of TCR-α and TCR-β chains of TCR. To achieve it, the TCR-α and TCR-β chains of this specification can be cloned in a single vector. Bicistronic constructs have been shown to overcome this obstacle. The use of TCR-α and TCR-β chains in between viral ribosome entry sites (IRES) leads to the coordinated expression of the two chains, because TCR-α and TCR-β chains are produced by a single transcript that is divided into two proteins during translation, thereby ensuring the production of equal molar ratios of TCR-α and TCR-β chains. (Schmitt et al. 2009).

[0213] The nucleic acid encoding the TCR of the present specification may be a codon optimized to increase expression from a host cell. Genetic code redundancy allows some amino acids to be encoded by more than one codon, but some codons are not "optimized" by other codons because of the relative availability of matching tRNA and other factors (Gustafsson et al., 2004). Modifying the TCR-α and TCR-β gene sequences so that each amino acid is encoded by the optimal codon for mammalian gene expression, as well as eliminating mRNA instability motifs or cryptic splicing sites, has been shown to significantly increase TCR-α and TCR-β gene expression (Scholten et al., 2006).

[0214] In addition, mispairing between introduced and endogenous TCR chains may result in the acquisition of specificities, which constitutes a significant risk of autoimmunity. For example, the formation of mixed TCR dimers may reduce the number of CD3 molecules available to form a correctly paired TCR complex, and therefore, can significantly reduce the functional avidity of cells expressing the introduced TCR (Kuball et al., 2007).

[0215] To reduce mispairing, the C-terminal domains of the TCR chains introduced in this specification can be modified to promote interchain affinity while reducing the ability of the introduced chains to pair with endogenous TCRs. These strategies may include replacing the human TCR-α and TCR-β C-terminal domains with mouse counterparts (murinized C-terminal domains); generating a second interchain disulfide bond in the C-terminal domain by introducing a second cysteine ​​residue into the TCR-α and TCR-β chains of the introduced TCR (cysteine ​​modification); exchanging the interacting residues of the C-terminal domains of the TCR-α and TCR-β chains ("knob-in-hole structure"); directly fusing the variable domains of the TCR-α and TCR-β chains to CD3ζ (CD3ζ fusion) (Schmitt et al. 2009).

[0216] In one embodiment, the host cell is structurally altered to express the TCR of this specification. In a preferred embodiment, the host cell is a human T cell or a T cell progenitor cell. In some embodiments, the T cell or T cell progenitor cell is obtained from a cancer patient. In other embodiments, the T cell or T cell progenitor cell is obtained from a healthy donor. The host cell of this specification can be allogeneic or autologous relative to the patient to be treated. In one embodiment, the host is a γ / δ T cell transformed to express an α / β TCR.

[0217] A "pharmaceutical composition" refers to a composition suitable for administration to humans in a medical setting. Preferably, the pharmaceutical composition is sterile and manufactured according to GMP guidelines.

[0218] The pharmaceutical composition comprises the peptide in free form or in the form of a pharmaceutically acceptable salt (see also above). In one aspect, the peptide described herein is in the form of a pharmaceutically acceptable salt. In another aspect, the peptide in the form of a pharmaceutically acceptable salt is in crystalline form.

[0219] In one aspect, the pharmaceutically acceptable salts described herein refer to salts having toxicity characteristics within an acceptable range for pharmaceutical use.

[0220] As used herein, "pharmaceutically acceptable salt" refers to a derivative of the disclosed peptides wherein the peptide is modified by an acid or an alkali salt of a pharmaceutical agent. For example, an acid salt is prepared by reacting a free base (generally where the neutral drug has a neutral -NH2 group) with a suitable acid. Suitable acids for preparing acid salts include organic acids such as acetic acid, propionic acid, hydroxy acids, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, salicylic acid, and the like, and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Conversely, alkali salt preparations of acidic groups present on a peptide are prepared using pharmaceutically acceptable alkali groups such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, and the like.

[0221] In one aspect, pharmaceutically acceptable salts can improve the solubility and / or stability of the peptides described herein. In another aspect, pharmaceutically acceptable salts described herein can be prepared from the corresponding carrier peptide or complex by conventional methods, such as reacting the peptide or complex described herein with an appropriate acid or base. In another aspect, pharmaceutically acceptable salts are in crystalline or semi-crystalline form. In another aspect, pharmaceutically acceptable salts can include, for example, Handbook of Pharmaceutical Salts: Properties, Selection, and Use by PH Stahl and CG Wermuth (Wiley-VCH 2002), LD Bighley, SM Berge, DC Monkhouse, Encyclopedia of Pharmaceutical Technology. Eds. J. Swarbrick and JC Boylan, Vol. 13, Marcel Dekker, Inc., New York, Basel, Hong Kong 1995, pp. 453-499, each of which is incorporated herein by reference in its entirety.

[0222] In particularly preferred embodiments, the pharmaceutical composition comprises the peptide in the form of acetic acid (acetate), trifluoroacetate or hydrochloric acid (chloride).

[0223] The agent of the present invention is preferably an immunotherapeutic agent, for example, a vaccine. The vaccine may be administered directly to the affected organ of the patient, or systemically by id, im, sc, ip and iv injection, or applied in vitro to cells from the patient or his cell line (which are then injected into the patient), or in vitro to a subpopulation of immune cells from the patient (which are then re-administered to the patient). If the nucleic acid is injected into the cells in vitro, it may be beneficial to transfect the cells to co-express immunostimulatory cytokines (such as interleukin-2). The peptide may be administered completely alone, or in combination with an immunostimulatory adjuvant (see below), or in combination with an immunostimulatory cytokine, or in an appropriate delivery system (such as liposomes). The peptide may also be conjugated to a suitable carrier (such as keyhole limpet hemocyanin (KLH) or mannan) to a suitable carrier (see WO 95 / 18145 and (Longenecker et al., 1993)). The peptide may also be labeled, may be a fusion protein, or may be a hybrid molecule. The peptides given in the present invention are expected to stimulate CD4 or CD8 T cells. However, CD8 T cell stimulation is more effective with the help of CD4 T-helper cells. Therefore, for MHC-I class epitopes that stimulate CD8 T cells, a fusion partner or fragment of a hybrid molecule provides an appropriate epitope for stimulating CD4 positive T cells. CD4- and CD8 stimulatory epitopes are well known in the art and include epitopes identified in the present invention. In one aspect, the vaccine comprises at least one peptide set forth in SEQ ID NO: 1 to SEQ ID NO: 489 and at least one additional peptide, preferably 2 to 50, more preferably 2 to 25, more preferably 2 to 20, and most preferably 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 peptides. The peptides may be derived from one or more specific TAAs and may bind to MHC class I molecules.

[0224] In another aspect, the present invention provides a nucleic acid (e.g., a polynucleotide) encoding a peptide or peptide variant of the present invention. The polynucleotide may be, for example, DNA, cDNA, PNA, RNA, or a combination thereof, which may be single-stranded and / or double-stranded, or a native or stabilized form of a polynucleotide (e.g., a polynucleotide having a thiophosphate backbone), and may or may not contain introns as long as it encodes a peptide. Of course, a polynucleotide can only encode a peptide that incorporates natural peptide bonds and contains natural amino acid residues. In another aspect, the present invention provides an expression vector that can express a polypeptide according to the present invention. For connecting polynucleotides, various methods have been developed, especially for DNA, by methods such as supplementing a vector with ligatable ends. For example, a complementary homopolymer track can be added to a DNA fragment, and then the DNA fragment is inserted into the vector DNA. Then, the vector and the DNA fragment are combined by hydrogen bonding of the complementary homopolymer tails to form a recombinant DNA molecule.

[0225] Synthetic linkers containing one or more restriction endonucleases provide another method for ligating DNA fragments to vectors. Synthetic linkers containing various restriction endonucleases can be purchased from a variety of sources, including International Biotechnologies Inc. (New Haven, Connecticut, USA).

[0226] The DNA encoding the polypeptide of the present invention is preferably modified by the polymerase chain reaction method used by Saiki et al. (Saiki et al., 1988). This method can be used to introduce DNA into a suitable vector (for example, by designing suitable restriction sites), and can also be used to modify DNA by other useful methods known in the art. If a viral vector is used, a poxvirus vector or an adenovirus vector is preferred.

[0227] Afterwards, the DNA (or in the case of a retroviral vector, RNA) may be expressed in a suitable host, thereby producing a polypeptide containing the peptide or variant of the present invention. Thus, the DNA encoding the peptide or variant of the present invention may be used according to known techniques, after appropriate modification using the methods described herein, to construct an expression vector, which is then used to transform a suitable host cell, thereby expressing and producing the polypeptide of the present invention. Such techniques include those disclosed in, for example, U.S. Patents 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648.

[0228] The DNA (or RNA in the case of retroviral vectors) encoding the polypeptide containing the compound of the invention may be added to a variety of other DNA sequences and introduced into a suitable host. The companion DNA will depend on the nature of the host, the manner in which the DNA is introduced into the host, and whether it is necessary to maintain it as an episome or to be combined with each other.

[0229] Generally, the DNA can be attached to an expression vector (such as a plasmid) in the proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such control functions are generally present in the expression vector. The vector is then introduced into the host by standard methods. Generally, not all hosts will be transformed by the vector. Therefore, it is necessary to select transformed host cells. Selection methods include inserting a DNA sequence into the expression vector with any necessary control elements that encodes a selectable attribute (such as antibiotic resistance) in the transformed cell.

[0230] Alternatively, the gene conferring such a selectable trait may be on another vector which is used to co-transform the desired host cell.

[0231] The host cells transformed with the recombinant DNA of the present invention are then cultured under appropriate conditions familiar to those skilled in the art as described herein and for a sufficient period of time to express the peptide which can then be recovered.

[0232] There are many known expression systems, including bacteria (such as E. coli and Bacillus subtilis), yeast (such as Saccharomyces cerevisiae), filamentous fungi (such as Aspergillus), plant cells, animal cells and insect cells. The system can be preferably mammalian cells, such as CHO cells from the ATCC Cell Biology Collection.

[0233] Typical mammalian cell constitutive expression vector plasmids include CMV or SV40 promoters containing a suitable poly A tail and resistance markers (such as neomycin). An example is pSVL obtained from Pharmacia (Piscataway, New Jersey, USA). An example of an inducible mammalian expression vector is pMSG, which can also be obtained from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS413-416, which are generally available from Stratagene Cloning Systems (La Jolla, California 92037, USA). Plasmids pRS403, pRS404, pRS405 and pRS406 are yeast integration plasmids (YIp), and yeast selectable markers HIS3, TRP1, LEU2 and URA3 are inserted. pRS413-416 plasmids are yeast centromere plasmids (Ycp). Vectors based on the CMV promoter (e.g., from Sigma-Aldrich) provide transient or stable expression, cytoplasmic expression or secretion, and N-terminal or C-terminal tags in different compositions of FLAG, 3xFLAG, c-myc or MATN. These fusion proteins can be used to detect, purify and analyze recombinant proteins. Dual-label fusions provide flexibility for detection.

[0234] The strong human cytomegalovirus (CMV) promoter regulatory region allows the expression of constitutive proteins in COS cells at levels as high as 1 mg / L. For weaker cell lines, protein levels are generally less than 0.1 mg / L. The presence of the SV40 replication origin will result in high-level replication of DNA in SV40 replication-permissive COS cells. For example, CMV vectors can contain the pMB1 (derivative of pBR322) replication origin in bacterial cells, the calcium-lactamase gene for ampicillin resistance selection in bacteria, the hGH polyA and f1 origin. Vectors containing the preproinsulin leader (PPT) sequence can use anti-FLAG antibodies, resins and plates to direct the secretion of FLAG fusion proteins into the culture medium for purification. Other vectors and expression systems used with various host cells are well known in the art.

[0235] In another embodiment, two or more peptides or peptide variants of the present invention are encoded and thus expressed in a continuous order (similar to a "beads on a string" construct). Upon reaching the target, the peptides or peptide variants may be linked or fused together via a linker amino acid stretch (e.g., LLLLLL) or they may be linked without any additional peptides between them. These constructs may also be used in cancer therapy and may induce immune responses involving MHC class I and MHC class II molecules.

[0236] The present invention also relates to a host cell, which is transformed with the polynucleotide vector construction of the present invention. The host cell can be a prokaryotic cell or a eukaryotic cell. In some cases, bacterial cells are preferred prokaryotic host cells, typically Escherichia coli strains, for example, Escherichia coli strain DH5 (obtained from Bethesda Research Laboratories, Bethesda, Maryland, USA) and RR1 (obtained from the American Type Culture Collection (ATCC, Rockville, Maryland, USA), ATCC No. 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells, such as cells in mouse, rat, monkey or human fibroblasts and colon cancer cell lines. Yeast host cells include YPH499, YPH500 and YPH501, which are generally available from Stratagene Cloning Systems, LaJolla, California 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells, CCL61 cells in ATCC, NIH Swiss mouse embryonic cells NIH / 3T3, CRL 1658 cells in ATCC, monkey kidney-derived COS-1 cells, CRL 1650 cells in ATCC, and human embryonic kidney cells No. 293 cells. Preferred insect cells are Sf9 cells, which can be transfected with baculovirus expression vectors. An overview of the selection of appropriate host cells for expression can be found in textbooks (Paulina Balbás and Argelia Lorence "Methods in Molecular Biology Recombinant Gene Expression, Reviews and Protocols" Part One, Second Edition, ISBN978-1-58829-262-9) and other literature known to the skilled person.

[0237] The transformation of suitable host cells containing the DNA structure of the present invention can be completed using well-known methods, usually depending on the type of vector used. For the transformation of prokaryotic host cells, see, for example, the literature of Cohen et al. (Cohen et al., 1972) and (Green and Sambrook, 2012). The transformation of yeast cells is described in the article of Sherman et al. (Sherman et al., 1986). The method described in Beggs (Beggs, 1978) is also very useful. For vertebrate cells, reagents for transfecting these cells, such as calcium phosphate and DEAE-dextran or liposome formulations, can be obtained from Stratagene Cloning Systems or Life Technologies (Gaithersburg, Maryland 20877, USA). Electroporation can also be used to transform and / or transfect cells, which is a well-known method in the art for transforming yeast cells, bacterial cells, insect cells and vertebrate cells.

[0238] Successfully transformed cells (i.e. cells containing the DNA construct of the present invention) can be identified by well-known methods (e.g. PCR). In addition, proteins present in the supernatant can be detected using antibodies.

[0239] It should be understood that certain host cells of the present invention are used to prepare the peptides of the present invention, such as bacterial cells, yeast cells and insect cells. However, other host cells may be useful for certain therapeutic methods. For example, antigen presenting cells (such as dendritic cells) can be used to express the peptides of the present invention so that they can be loaded into the corresponding MHC molecules of humans. Therefore, the present invention provides a host cell containing the nucleic acid or expression vector of the present invention.

[0240] In a preferred embodiment, the host cell is an antigen presenting cell, in particular a dendritic cell or an antigen presenting cell. On April 29, 2010, the U.S. Food and Drug Administration (FDA) approved a recombinant fusion protein containing prostatic acid phosphatase (PAP) for the treatment of asymptomatic or mildly symptomatic metastatic HRPC (Rini et al., 2006; Small et al., 2006).

[0241] In another aspect, the present invention provides a method for preparing a peptide and a variant thereof, the method comprising culturing a host cell and isolating the peptide from the host cell or its culture medium.

[0242] In another embodiment, the peptide, nucleic acid or expression vector of the present invention is used in medicine. For example, the peptide or its variant can be prepared as an intravenous (iv) injection, a subcutaneous (sc) injection, an intradermal (id) injection, an intraperitoneal (ip) injection, or an intramuscular (im) injection. Preferred methods for peptide injection include sc, id, ip, im and iv injection. Preferred methods for DNA injection are id, im, sc, ip and iv injection. For example, 50 μg to 1.5 mg, preferably 125 μg to 500 μg of peptide or DNA is administered, depending on the specific peptide or DNA. The above dosage range has been successfully used in previous experiments (Walter et al., 2012).

[0243] The polynucleotides used for active immunization can be in a substantially purified form or can be coated in a carrier or delivery system. The nucleic acid may be DNA, cDNA, PNA, RNA, or a combination thereof. The design and introduction of such nucleic acids are well known in the art. For example, there is an overview of this in the literature (Teufel et al., 2005). Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing immune responses is not yet fully understood. Suitable vectors and delivery systems include viral DNA and / or RNA, such as systems based on adenovirus, vaccinia virus, retrovirus, herpes virus, adeno-associated virus, or mixed viruses containing more than one viral element. Non-viral delivery systems include cationic liposomes and cationic polymers, which are well known systems in the field of DNA delivery. Physical delivery systems can also be used, such as through a "gene gun". The peptide or peptide encoded by the nucleic acid can be a fusion protein, for example, containing epitopes that stimulate T cells to carry out the above-mentioned CDR.

[0244] The medicaments of the present invention may also include one or more adjuvants. Adjuvants are substances that non-specifically enhance or strengthen immune responses (e.g., immune responses to an antigen mediated by CD8-positive T cells and helper T (TH) cells) and are therefore considered useful for the medicaments of the present invention. Suitable adjuvants include (but are not limited to) 1018ISS, aluminum salts, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or flagellin-derived TLR5 ligand, FLT3 ligand, GM-CSF, IC30, IC31, imiquimod resiquimod, ImuFactIMP321, interleukin IL-2, IL-13, IL-21, interferon α or β, or their PEGylated derivatives, IS Patch, ISS, ISCOMATRIX, ISCOMs, LipoVac, MALP2, MF59, monophosphatidylserine A, Montanide IMS1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, oil-in-water and water-in-oil emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, Vector systems, poly(lactide-co-glycolide) [PLG] and dextran-based microparticles, recombinant human lactoferrin SRL172, virosomes and other virus-like particles, YF-17D, VE GF trap, R848, β-glucan, Pam3Cys, Aquila's QS21 stimulator derived from saponins, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil or Superfos. Preferred adjuvants are Freund's adjuvant or GM-CSF. Some dendritic cell-specific immunoadjuvants (such as MF59) and methods for their preparation have been described previously (Allison and Krummel, 1995). Cytokines may also be used. Some cytokines directly affect the migration of dendritic cells to lymphoid tissues (e.g., TNF-), accelerate the maturation of dendritic cells into effective antigen-presenting cells of T lymphocytes (e.g., GM-CSF, IL-1 and IL-4) (U.S. Patent No. 5,849,589, specifically incorporated herein by reference in its entirety), and act as immune adjuvants (e.g., IL-12, IL-15, IL-23, IL-7, IFN-α, IFN-β) (Gabrilovich et al., 1996).

[0245] CpG immunostimulatory oligonucleotides have been reported to enhance the effects of adjuvants in vaccines. Without being bound by theory, CpG oligonucleotides may act by priming the innate (non-adaptive) immune system through Toll-like receptors (TLRs), primarily TLR9. CpG-induced TLR9 activation enhances antigen-specific humoral and cellular responses to a variety of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cell vaccines, and polysaccharide conjugates in prophylactic and therapeutic vaccines. More importantly, it enhances maturation and differentiation of dendritic cells, leading to enhanced activation of TH1 cells and enhanced cytotoxic T lymphocyte (CTL) generation, even with the loss of CD4 T cell expression. The TH1 shift induced by TLR9 activation is maintained even in the presence of vaccine adjuvants, such as alum or incomplete Freund's adjuvant (IFA), which normally promote a TH2 shift. CpG oligonucleotides exhibit stronger adjuvant activity when prepared or co-administered with other adjuvants or formulations, such as microparticles, nanoparticles, fat emulsions or similar preparations, which are particularly necessary to induce strong responses when the antigen is relatively weak. They can also accelerate immune responses, reducing the antigen dose by about two orders of magnitude, and in some experiments, similar antibody responses can be produced to full-dose vaccines without CpG (Krieg, 2006). U.S. Patent No. 7726705B1 describes the use of CpG oligonucleotides, non-nucleic acid adjuvants and antigens in combination to promote antigen-specific immune responses. A CpG TLR9 antagonist is dSLIM (double stem loop immunomodulator) from Mologen (Berlin, Germany), which is a preferred component of the pharmaceutical composition of the present invention. Other TLR binding molecules, such as RNA binding TLR7, TLR8 and / or TLR9, can also be used.

[0246] Other useful adjuvant examples include (but are not limited to) chemically modified CpG (e.g., CpR, Idera), dsRNA mimics, such as Poly(I:C) and its derivatives (e.g., AmpliGen, Hiltonol, poly-(ICLC), poly(IC-R), poly(I:C12U)), non-CpG bacterial DNA or RNA, and immunologically active small molecules and antibodies, such as cyclophosphamide, sunitinib, Celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib, VEGF Trap, ZD2171, AZD217 1, anti-CTLA4, other antibodies targeting major structures of the immune system (e.g., anti-CD40, anti-TGFβ, anti-TNFα receptors), and SC58175, all of which may have therapeutic effects and / or act as adjuvants. The amount and concentration of adjuvants and additives useful in the present invention can be readily determined by the skilled artisan without undue experimentation.

[0247] Preferred adjuvants are anti-CD40, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon α, CpG oligonucleotides and derivatives, poly (I:C) and derivatives, RNA, sildenafil, and microparticle preparations of PLG or virosomes.

[0248] In a preferred embodiment of the pharmaceutical composition of the present invention, the adjuvant is selected from a preparation containing colony stimulating factors, such as granulocyte macrophage colony stimulating factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod, resiquimod and interferon-α.

[0249] In a preferred embodiment of the pharmaceutical composition of the present invention, the adjuvant is selected from a preparation containing colony stimulating factors, such as granulocyte macrophage colony stimulating factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod and resiquimod. In a preferred embodiment of the pharmaceutical composition of the present invention, the adjuvant is cyclophosphamide, imiquimod or resiquimod. More preferred adjuvants are Montanide IMS 1 312, Montanide ISA 206, Montanide ISA50V, Montanide ISA-51, poly-ICLC and anti-CD40 mAb or a combination thereof.

[0250] This combination drug is used for parenteral injection, such as subcutaneous, intradermal, intramuscular injection, and can also be taken orally. For this reason, peptides and other selective molecules are decomposed or suspended in a pharmaceutical carrier, preferably an aqueous carrier. In addition, the composition may contain excipients, such as buffers, binders, shock agents, diluents, spices, lubricants, etc. These peptides can also be used in combination with immunostimulants, such as cytokines. More excipients that can be used for such compositions can be found in books such as Handbook of Pharmaceutical Excipients (Kibbe, 2000) written by A.Kibbe. This combination drug can be used to prevent, prevent and / or treat adenomas or cancerous diseases. For example, there are example preparations in EP2112253.

[0251] In one aspect, the peptides or other molecules described herein can be combined with an aqueous carrier. In one aspect, the aqueous carrier is selected from ion exchangers, alumina, aluminum stearate, magnesium stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glycerol mixtures of saturated vegetable fatty acids, salts or electrolytes, such as esters of protamine sulfate, disodium hydrogen phosphate, dicalcium phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyvinyl pyrrolidone-vinyl acetate, cellulosic substances (e.g., microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate), starch, lactose monohydrate, mannitol, trehalose sodium lauryl sulfate and cross-linked sodium carboxymethylcellulose, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, polymethacrylates, waxes, polyethylene-polyoxypropylene block polymers and lanolin.

[0252] On the one hand, aqueous carriers contain multiple components, such as water and non-aqueous carrier components, such as those described herein. On the other hand, when combined with peptides or other molecules described herein, aqueous carriers can improve properties, such as improving solubility, effectiveness and / or improving immunotherapy. In addition, the composition may include excipients, such as buffers, binders, shock agents, diluents, spices, lubricants, etc. "Pharmaceutical diluents" may include solvents, fillers, stabilizers, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delay agents, etc., which are physiologically compatible. Examples of pharmaceutical diluents include one or more of saline, phosphate buffered saline, dextrose, glycerol, ethanol, etc. and their compositions. In many cases, it is preferred to include one or more isotonic agents (e.g., sugars such as trehalose and sucrose), polyols (e.g., mannitol, sorbitol) or sodium chloride in the composition. Pharmaceutical substances (e.g., wetting agents) or small amounts of auxiliary substances (e.g., wetting agents or emulsifiers, preservatives or buffers) are also within the scope of the present invention. In addition, the composition may contain excipients such as buffers, binders, blasting agents, diluents, flavors and lubricants. It is important to recognize that the immune response triggered by the vaccine of the present invention attacks cancer at different cellular stages and different stages of development. And different cancer-related signaling pathways are attacked. This is an advantage over other vaccines, which only target one or a few targets, which may cause tumors to easily adapt to attacks (tumor escape). In addition, not all individual tumors express the same pattern of antigens. Therefore, the combination of several tumor-associated peptides ensures that each tumor bears at least some targets. The composition is designed in such a way that it is expected that each tumor may express several antigens and cover several independent pathways required for tumor growth and maintenance. Therefore, the vaccine can be easily "off-the-shelf" for a larger patient population. This means that patients who are pre-selected for vaccine treatment can be limited to HLA typing, without any additional biomarker assessment of antigen expression, but still ensure that multiple targets are attacked by the induced immune response at the same time, which is important for efficacy (Banchereau et al., 2001; Walter et al., 2012).

[0253] As used herein, the term "scaffold" refers to a molecule that specifically binds to a (e.g., antigen) determinant. In one embodiment, a scaffold is capable of directing an entity to which it is attached (e.g., a (second) antigen binding moiety) to a target of interest, e.g., to a specific type of tumor cell or a tumor stroma bearing an antigenic determinant (e.g., a complex of a peptide and MHC according to the present application). In another embodiment, the scaffold is capable of initiating a signaling pathway through its target antigen (e.g., a T cell receptor complex antigen). Scaffolds include, but are not limited to, antibodies and fragments thereof, antigen binding regions of antibodies comprising an antibody heavy chain variable region and an antibody light chain variable region, bound proteins comprising at least one ankyrin repeat motif and a single domain antigen binding (SDAB) molecule, an aptamer, a (soluble) TCR, and (modified) cells, such as allogeneic or autologous T cells. In order to assess whether a molecule is a scaffold that binds to a target, a binding assay may be performed.

[0254] "Specific" binding means that the scaffold binds better to the peptide-MHC complex of interest than to other natural peptide-MHC complexes, to the extent that a scaffold with active molecules capable of killing cells bearing a specific target is not able to kill another cell without a specific target but presenting one or more other peptide-MHC complexes. If the peptide of the cross-reactive peptide-MHC is not natural, i.e., not from the human HLA-peptide group, binding to other peptide-MHC complexes is irrelevant. Assays for assessing target cell killing are well known in the art. They should be performed with target cells (primary cells or cell lines) presenting unaltered peptide-MHC or with cells loaded with the peptide so as to reach the level of natural peptide-MHC. Each scaffold may include a label, which can be detected by determining the presence or absence of a signal provided by the label. For example, the scaffold may be labeled with a fluorescent dye or any other suitable cell marker molecule. Such marker molecules are well known in the art. For example, fluorescent labeling with fluorescent dyes can provide visualization of bound aptamers by fluorescence or laser scanning microscopy or flow cytometry.

[0255] Each scaffold can be conjugated to a second active molecule (eg, IL-21, anti-CD3, anti-CD28).

[0256] For further information on polypeptide scaffolds, see, for example, the background section of WO 2014 / 071978A1, which is incorporated herein by reference.

[0257] The present invention also relates to aptamers. Aptamers (e.g., see WO 2014 / 191359 and documents cited therein) are short single-stranded nucleic acid molecules that can fold into a defined three-dimensional structure and recognize a specific target structure. They appear to be a suitable alternative for developing targeted therapies. Aptamers have been shown to selectively bind to complex targets with high affinity and specificity.

[0258] Aptamers that recognize cell surface molecules have been identified over the past decade and provide a means for developing diagnostic and therapeutic approaches. Aptamers have been shown to be virtually non-toxic and non-immunogenic, and therefore, are promising candidates for biomedical applications. Aptamers, such as prostate-specific membrane antigen-recognizing aptamers, have been successfully used for targeted therapy and have been shown to function in xenografts in in vivo models. In addition, aptamers that recognize specific tumor cell lines have also been identified.

[0259] DNA aptamers can be selected to reveal broad-spectrum recognition properties for various cancer cells, especially those derived from solid tumors, while non-tumorigenic and predominantly healthy cells are not recognized. If the identified aptamers not only recognize tumor-specific subtypes but also interact with a range of tumors, this makes the aptamers suitable as so-called broad-spectrum diagnostics and therapeutics.

[0260] Furthermore, investigation of the cell binding behavior using flow cytometry revealed that the aptamers displayed good affinity in the nanomolar range.

[0261] Aptamers are used for diagnostic and therapeutic purposes. Furthermore, it could also be shown that some aptamers are taken up by tumor cells and thus can serve as molecular vehicles for the targeted delivery of anticancer agents, such as siRNA into tumor cells.

[0262] Aptamers can be selected against complex targets such as cells and tissues and complexes of peptides according to the invention comprising, preferably including, a sequence according to any of SEQ ID NO 1 to SEQ ID NO 489 and MHC molecules using the cell SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique.

[0263] The peptides of the present invention can be used to generate and develop specific antibodies against MHC / peptide complexes. These antibodies can be used therapeutically to target toxins or radioactive substances to diseased tissue. Another use of these antibodies is to target radionuclides to diseased tissue for imaging purposes (such as PET). This can help detect small metastases or determine the size and exact location of diseased tissue.

[0264] Therefore, another aspect of the present invention is a method for producing a recombinant antibody that specifically binds to class I or II human major histocompatibility complex (MHC) complexed with an HLA-restricted antigen, the method comprising: immunizing a genetically engineered non-human mammal containing cells expressing the major histocompatibility complex (MHC) class I or II with a soluble form of a (MHC) class I or II molecule complexed with an HLA-restricted antigen (preferably a peptide according to the present invention); separating mRNA molecules from antibody-producing cells of the non-human mammal; producing a phage display library that displays protein molecules encoded by the mRNA molecules; and isolating at least one phage from the phage display library, the at least one phage displaying that the antibody specifically binds to the human major histocompatibility complex (MHC) class I or II complexed with the HLA-restricted antigen.

[0265] Therefore, another aspect of the present invention provides an antibody that specifically binds to a class I or II human major histocompatibility complex (MHC) complexed with an HLA-restricted antigen, wherein the antibody is preferably a polyclonal antibody, a monoclonal antibody, a bispecific antibody and / or a chimeric antibody.

[0266] Corresponding methods for producing such antibodies and single-chain class I major histocompatibility complexes, as well as other tools for producing these antibodies are disclosed in WO 03 / 068201, WO 2004 / 084798, WO 01 / 72768, WO 03 / 070752 and in publications (Cohen et al., 2003a; Cohen et al., 2003b; Denkberg et al., 2003), all of which are incorporated herein by reference in their entirety for the purposes of the present invention.

[0267] Preferably, the antibody binds to the complex with an affinity of less than 20 nanomolar, preferably less than 10 nanomolar, which is also considered "specific" in the context of the present invention.

[0268] The present invention relates to a peptide comprising a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 489 or a variant of the sequence having 88% homology (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 489, or a variant that induces T cell cross-reaction with the variant peptide, wherein the peptide is not a basic full-length polypeptide.

[0269] The present invention further relates to a peptide comprising a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 489, or a variant having at least 88% homology (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 489, wherein the total length of the peptide or variant is 8 to 100, preferably 8 to 30, most preferably 8 to 14 amino acids.

[0270] The present invention further relates to the peptides of the present invention, which have the ability to bind to major histocompatibility complex (MHC) class I or II molecules.

[0271] The present invention further relates to the peptides of the present invention, wherein the peptide consists of or essentially consists of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 489.

[0272] The present invention further relates to the peptides of the present invention, wherein the peptide is (chemically) modified and / or comprises non-peptide bonds.

[0273] The invention further relates to the peptides of the invention, wherein the peptide is part of a fusion protein, in particular comprising the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or wherein the peptide is fused to an antibody (eg, a dendritic cell-specific antibody).

[0274] The present invention further relates to a nucleic acid encoding a peptide according to the present invention, with the proviso that the peptide is not a complete (full) human protein.

[0275] The present invention further relates to a nucleic acid according to the present invention, which is DNA, cDNA, PNA, RNA, or a combination thereof.

[0276] The present invention further relates to an expression vector capable of expressing the nucleic acid of the present invention.

[0277] The present invention further relates to a peptide of the present invention, a nucleic acid of the present invention or a pharmaceutical expression vector of the present invention, in particular for use in treating lung cancer (including NSCLC and SCLC).

[0278] The present invention further relates to a host cell comprising the nucleic acid according to the invention or the expression vector according to the invention.

[0279] The present invention further relates to the host cell of the present invention, which is an antigen presenting cell, preferably a dendritic cell.

[0280] The present invention further relates to a method of formulating a peptide of the present invention, said method comprising culturing the host cell of the present invention and isolating the peptide from said host cell or its culture medium.

[0281] The present invention further relates to the method of the present invention, wherein the antigen is carried onto the class I or II MHC molecules expressed on the surface of suitable antigen presenting cells by binding to a sufficient amount of antigen containing antigen presenting cells.

[0282] The present invention further relates to the method of the present invention, wherein the antigen presenting cell comprises an expression vector capable of expressing a peptide comprising SEQ ID NO: 1 to SEQ ID NO: 489 or said variant amino acid sequence.

[0283] The present invention further relates to activated T cells produced by the method of the present invention, wherein the T cells selectively recognize a cell that abnormally expresses a polypeptide comprising an amino acid sequence of the present invention.

[0284] The present invention further relates to a method for killing target cells of a patient, wherein the target cells of the patient abnormally express a polypeptide comprising any amino acid sequence of the present invention, the method comprising administering an effective amount of T cells of the present invention to the patient.

[0285] The present invention further relates to the use of any of the peptides, a nucleic acid of the present invention, an expression vector of the present invention, a cell of the present invention, a cytotoxic T lymphocyte activated as a medicament or for the manufacture of a medicament. The present invention further relates to a use of the present invention, wherein the medicament is effective against cancer.

[0286] The present invention further relates to a use of the present invention, wherein the medicament is a vaccine. The present invention further relates to a use of the present invention, wherein the medicament is effective against cancer.

[0287] The present invention further relates to the use of the peptides according to the present invention, wherein the cancer cells are lung cancer (including NSCLC and SCLC) cells or other solid or hematological tumor cells, such as: acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, bladder cancer, uterine cancer. The present invention further relates to a specific marker protein and biomarker based on the peptides of the present invention, herein referred to as a "target", which can be used to diagnose and / or judge the prognosis of lung cancer (including NSCLC and SCLC). The present invention also relates to these new targets for cancer treatment.

[0288] The term "antibody" herein is defined in a broad sense, including both polyclonal and monoclonal antibodies. In addition to complete or "whole" immunoglobulin molecules, the term "antibody" also includes fragments (such as CDR, Fv, Fab and Fc fragments) or polymers of these immunoglobulin molecules and humanized immunoglobulin molecules, as long as they exhibit any desired attributes of the present invention (e.g., specific binding of lung cancer (including NSCLC and SCLC) marker (poly) peptides, delivering toxins to lung cancer (including NSCLC and SCLC) cells when the expression level of cancer marker genes increases, and / or inhibiting the activity of lung cancer (including NSCLC and SCLC) marker polypeptides).

[0289] Whenever possible, the antibodies of the present invention may be purchased from commercial sources. The antibodies of the present invention may also be made using known methods. The skilled artisan will appreciate that full-length lung cancer (including NSCLC and SCLC) marker polypeptides or fragments thereof may be used to prepare the antibodies of the present invention. The polypeptides used to generate the antibodies of the present invention may be partially or completely purified from natural sources or may be produced using recombinant DNA technology.

[0290] For example, a cDNA encoding a peptide of the present invention, for example, a peptide according to SEQ ID NO: 1 to SEQ ID NO: 489, or a variant or fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect or mammalian cells), after which the recombinant protein can be purified and used to produce a monoclonal or polyclonal antibody preparation that specifically binds to a lung cancer (including NSCLC and SCLC) marker polypeptide used to produce the antibody of the present invention.

[0291] Those skilled in the art will recognize that two or more different sets of monoclonal antibodies or polyclonal antibodies can maximize the possibility of obtaining an antibody with the specificity and affinity required for the intended use (e.g., ELISA, immunohistochemistry, in vivo imaging, immunotoxin therapy). Depending on the use of the antibody, its desired activity is tested using known methods (e.g., ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on the generation and testing of antibodies, see, for example, Greenfield, 2014 (Greenfield, 2014)). For example, the antibody can be tested using ELISA or immunoblotting, immunohistochemical staining of formalin-fixed cancer tissue or frozen tissue sections. After initial in vitro characterization, antibodies for therapeutic or in vivo diagnostic use are tested according to known clinical testing methods.

[0292] The term "monoclonal antibody" as used herein refers to an antibody obtained from a large number of homogeneous antibodies, i.e., a population of antibodies consisting of identical antibodies, except for natural mutations that may be present in small amounts. The monoclonal antibodies described herein specifically include "chimeric" antibodies, in which a portion of the heavy chain and / or light chain is identical (homogeneous) to the corresponding sequence of antibodies obtained from a specific species or belonging to a specific antibody type and subtype, while the remaining chain is identical (homogeneous) to the corresponding sequence of antibodies obtained from other species or belonging to a specific antibody type and subtype, as well as fragments of these antibodies, as long as they exhibit the expected antagonistic activity (U.S. Patent No. 4,816,567, which is hereby incorporated in its entirety).

[0293] The monoclonal antibodies of the invention may be prepared using a hybridoma method. In the hybridoma method, mice or other appropriate host animals are typically immunized with an immunizing agent to elicit or produce antibodies that will specifically bind to the immunizing agent. Alternatively, lymphocytes may be immunized in vitro.

[0294] Monoclonal antibodies can also be made by recombinant DNA methods, such as described in U.S. Patent No. 4816567. DNA encoding the monoclonal antibodies of the invention can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that specifically bind to genes encoding mouse antibody heavy and light chains).

[0295] In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments of antibodies, particularly Fab fragments, can be accomplished using conventional techniques known in the art. For example, digestion can be accomplished using papain. Examples of papain digestion are described in WO 94 / 29348 and U.S. Patent No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen-binding fragments, called Fab fragments (each with one antigen binding site) and a residual Fc fragment. Pepsin treatment produces a F(ab′)2 fragment and a pFc′ fragment.

[0296] Antibody fragments, whether or not attached to other sequences, may include insertions, deletions, substitutions, or other selective modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications may provide additional properties, such as deletion / addition of amino acids that can bind to disulfide bonds to increase their biological lifespan, alter their secretory properties, etc. In any case, antibody fragments must possess biologically active properties, such as binding activity, modulation of binding domain binding, etc. The functional or active regions of antibodies can be determined by genetic mutations in specific regions of the protein, followed by expression and testing of the expressed polypeptides. These methods are well known to those skilled in the art and may include site-specific genetic mutations of nucleic acids encoding antibody fragments.

[0297] The antibodies of the present invention may further include humanized antibodies or human antibodies. The humanized form of non-human (e.g., mouse) antibodies is a chimeric antibody immunoglobulin, immunoglobulin chain or fragment thereof (e.g., Fv, Fab, Fab' or other antigen-binding sequences of antibodies), which contains minimal sequences obtained from non-human immunoglobulins. Humanized antibodies include human immunoglobulins (receptor antibodies) in which residues from the complementary determining regions (CDRs) of the receptor are replaced by residues from CDRs of non-human species (donor antibodies) (e.g., mice, rats or rabbits with specificity, affinity and ability). In some cases, Fv framework (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies may also include residues that are found neither in the receptor antibody nor in the imported CDR or framework sequences. In general, humanized antibodies will include nearly all of at least one, usually two, variable domains, wherein all or nearly all of the CDR regions correspond to regions of non-human immunoglobulins and all or nearly all of the FR regions are regions of the same sequence of human immunoglobulins. Ideally, the humanized antibody will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0298] Methods for humanizing non-human antibodies are well known in the industry. In general, humanized antibodies have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are often referred to as "import" residues and are usually obtained from an "import" variable domain. Humanization can be essentially accomplished by replacing rodent CDRs or CDR sequences with corresponding human antibody sequences. Therefore, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), in which much less than the complete human variable domain is replaced by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are replaced by residues from analogous sites in rodent antibodies.

[0299] Transgenic animals (e.g., mice) that can produce complete human antibodies after immunization when endogenous immunoglobulin production is absent can be used. For example, it has been described that homozygous deletion of the antibody heavy chain joining region gene in chimeric and germline mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germline immunoglobulin gene array in this germline mutant mouse will result in the generation of human antibodies after antigen challenge. Human antibodies can also be produced in phage display libraries.

[0300] The antibodies of the present invention are preferably administered to a subject in the form of a pharmaceutical carrier. Typically, an appropriate amount of a pharmaceutical salt is used in the formulation to make the formulation isotonic. Examples of pharmaceutical carriers include physiological saline, Ringer's solution, and glucose solution. The pH of the solution is preferably about 5 to 8, more preferably about 7 to 7.5. In addition, carriers also include sustained-release preparations, such as solid hydrophobic polymer semipermeable matrices containing antibodies, wherein the matrix is ​​in the form of tangible articles, such as films, liposomes, or microparticles. It is well known to those skilled in the art that certain carriers may be more preferred, depending on, for example, the route of administration and concentration of the antibody. The antibody can be administered to a subject, patient, or cell by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular) or by other methods such as infusion to ensure that it is delivered to the blood in an effective form. These antibodies can also be administered via intratumoral or peritumoral routes to exert local and systemic therapeutic effects. Local or intravenous injection is preferred.

[0301] The effective dose and schedule of antibody administration can be determined empirically, and making such decisions is within the technical scope of the industry. Those skilled in the art will understand that the dose of antibody that must be administered will vary depending on factors such as the subject receiving the antibody, the route of administration, the specific type of antibody used, and other drugs being used. The usual daily dose of the antibody used alone may be from about 1 μg / kg to a maximum of 100 mg / kg body weight or more, depending on the above factors. After administration of the antibody, preferably lung cancer (including NSCLC and SCLC), the efficacy of the therapeutic antibody can be assessed by various methods well known to technicians. For example, the size, number and / or distribution of cancer in a subject receiving treatment can be monitored using standard tumor imaging techniques. Antibodies administered for treatment can prevent tumor growth, cause tumor shrinkage, and / or prevent the development of new tumors compared to the course of the disease when the antibody is not administered, and such antibodies are antibodies that are effective in treating cancer.

[0302] Another aspect of the present invention proposes a method for preparing a soluble T cell receptor (sTCR) that recognizes a specific peptide-MHC complex. Such soluble T cell receptors can be produced from specific T cell clones, and their affinity can be increased by targeted mutagenesis of the complementary determining region. For the purpose of T cell receptor selection, phage display can be used (US 2010 / 0113300, (Liddy et al., 2012)). For the purpose of stabilizing T cell receptors during phage display and when actually used as drugs, α and β chains can be connected through non-natural disulfide bonds, other covalent bonds (single-chain T cell receptors) or through dimerization domains (Boulter et al., 2003; Card et al., 2004; Willcox et al., 1999). T cell receptors can be connected to toxins, drugs, cytokines (see US2013 / 0115191), domains to recruit effector cells, such as anti-CD3 domains, etc., in order to perform specific functions on target cells. Furthermore, it may be expressed in T cells for adoptive transfer. Further information can be found in WO 2004 / 033685A1 and WO 2004 / 074322A1. Combinations of sTCRs are described in WO 2012 / 056407A1. Further methods of preparation are disclosed in WO 2013 / 057586A1.

[0303] Furthermore, the peptides and / or TCRs or antibodies or other binding molecules of the invention can be used to confirm a pathologist's diagnosis of cancer based on a biopsy sample.

[0304] The antibody or TCR can also be used in in vivo diagnostic experiments. Generally, the antibody is labeled with a radionuclide (such as 111In, 99Tc, 14C, 131I, 3H, 32P or 35S), so that the tumor can be localized by immunoscintigraphy. In one embodiment, the antibody or fragment thereof binds to the extracellular domain of two or more protein targets selected from the group including the above-mentioned proteins, and the affinity value (Kd) is less than 1x10μM.

[0305] Diagnostic antibodies can be labeled with probes suitable for detection by various imaging methods. Probe detection methods include, but are not limited to, fluorescence, light, confocal and electron microscopy methods; magnetic resonance imaging and spectroscopy techniques; fluoroscopy, computer tomography and positron emission tomography. Suitable probes include, but are not limited to, fluorescein, rhodamine, eosin and other fluorophores, radioisotopes, gold, gadolinium and other rare earths, paramagnetic magnets, fluorine-18 and other positron-emitting radionuclides. In addition, the probes may be bifunctional or multifunctional and can be detected by more than one of the above methods. These antibodies can be labeled directly or indirectly with the probes described. The connection of antibody probes includes covalent connection of probes, fusion of probes to human antibodies, and covalent connection of chelating compounds to bind probes, as well as other methods well known in the industry. For immunohistochemistry methods, disease tissue samples may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin. Fixed or embedded sections include samples contacted with labeled primary and secondary antibodies, wherein the antibodies are used to detect the expression of proteins in situ.

[0306] Another aspect of the invention includes a method for preparing activated T cells in vitro, the method comprising connecting T cells in vitro with human MHC molecules loaded with antigens, which are expressed on the surface of suitable antigen presenting cells for a sufficient period of time to activate the T cells in an antigen-specific manner, wherein the antigen is a peptide according to the invention. Preferably, a sufficient amount of antigen is used together with the antigen presenting cells.

[0307] Preferably, the TAP peptide transporter in mammalian cells is deficient or has a reduced level or reduced function. Suitable cells lacking the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is a transporter associated with antigen processing. The human peptide-carrying defective cell line T2 is from the American Type Culture Collection (ATCC, 12301 Parklawn Drive, Rockville, Maryland 20852, USA) catalog number CRL1992; the Drosophila cell line Schneider No. 2 is from the ATCC catalog CRL 19863; the mouse RMA-S cell line Ljunggren et al. described (Ljunggren and Karre, 1985).

[0308] Preferably, the host cells do not substantially express MHC class I molecules before transfection. The stimulatory factor cells also preferably express molecules that play an important role in T cell co-stimulatory signals, such as any of B7.1, B7.2, ICAM-1 and LFA 3. Nucleic acid sequences of a large number of MHC class I molecules and co-stimulatory molecules are publicly available from GenBank and EMBL databases.

[0309] When an MHC class I epitope is used as an antigen, the T cell is a CD8 positive T cell.

[0310] If the antigen presenting cell is transfected to express such an epitope, preferably the cell comprises an expression vector capable of expressing a peptide or variant amino acid sequence comprising SEQ ID NO: 1 to SEQ ID NO: 489.

[0311] Other methods can be used to generate T cells in vitro. For example, autologous tumor-infiltrating lymphocytes can be used to generate CTLs. Plebanski et al. (Plebanski et al., 1995) used autologous peripheral blood lymphocytes (PLB) to generate T cells. In addition, it is also possible to pulse dendritic cells with peptides or polypeptides or to generate autologous T cells by infection with recombinant viruses. In addition, B cells can be used to prepare autologous T cells. In addition, macrophages pulsed with peptides or polypeptides or infected with recombinant viruses can be used to prepare autologous T cells. S. Walter et al. (Walter et al., 2003) described the in vitro activation of T cells by using artificial antigen presenting cells (aAPC), which is also a suitable method for generating T cells that act on selected peptides. In the present invention, aAPCs are generated by coupling preformed MHC:peptide complexes to polystyrene particles (microspheres) according to the biotin:streptavidin biochemical method. This system enables precise regulation of the MHC density on aAPCs, which allows for the selective induction of high- or low-avidity, efficient antigen-specific T-cell responses in blood samples. In addition to the MHC:peptide complexes, aAPCs should also carry other proteins with co-stimulatory activity, such as anti-CD28 antibodies coupled to their surface. In addition, such aAPC-based systems often require the addition of appropriate soluble factors, for example, cytokines such as interleukin 12.

[0312] T cells can also be made from allogeneic cells, a method described in detail in WO 97 / 26328, which is incorporated herein by reference. For example, in addition to Drosophila cells and T2 cells, other cells can be used to present peptides, such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, and vaccinia-infected target cells. In addition, plant viruses can also be used (for example, see Porta et al. (Porta et al., 1994) which describes the development of cowpea mosaic virus as a high-yield system for presenting foreign peptides.

[0313] The activated T cells are directly targeted to the peptides of the present invention, which is helpful for treatment. Therefore, another aspect of the present invention provides activated T cells prepared by the aforementioned method of the present invention.

[0314] The activated T cells prepared by the above method will selectively recognize the abnormally expressed polypeptide containing the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 489.

[0315] Preferably, the T cell recognizes the cell by interacting (e.g., binding) with its TCR containing the HLA / peptide complex. T cells are useful cells in a method of killing a target cell in a patient, wherein the target cell abnormally expresses a polypeptide containing the amino acid sequence of the present invention. Such a patient is administered an effective amount of activated T cells. The T cells administered to the patient may be derived from the patient and activated as described above (i.e., they are autologous T cells). Alternatively, the T cells are not derived from the patient, but from another person. Of course, it is preferred that the donor is a healthy person. The inventors use "healthy individual" to refer to a person who is generally in good condition, preferably has a competent immune system, and more preferably does not have any disease that can be easily tested or detected.

[0316] According to the present invention, the in vivo target cells of CD8-positive T cells may be tumor cells (sometimes expressing MHC class II antigens) and / or stromal cells (tumor cells) surrounding the tumor (sometimes also expressing MHC class II antigens; (Dengjel et al., 2006)).

[0317] The T cells of the present invention can be used as an active ingredient in a therapeutic composition. Therefore, the present invention also provides a method for killing a patient's target cells, wherein the patient's target cells abnormally express a polypeptide containing the amino acid sequence of the present invention, the method comprising administering to the patient an effective amount of the T cells.

[0318] The term "abnormal expression" used by the inventors also includes overexpression of a polypeptide compared to the normal expression level, or expression of the gene in a tumor while not expressed in a tumor-derived tissue. "Overexpression" means that the level of the polypeptide is at least 1.2 times that in a normal tissue; preferably at least 2 times that in a normal tissue, and more preferably at least 4 or 6 times that in a normal tissue.

[0319] T cells can be prepared by methods known in the art (eg, as described above).

[0320] T cell adoptive transfer protocols are well known in the art. Reviews can be found in: Gattioni et al. and Morgan et al. (Gattinoni et al., 2006; Morgan et al., 2006).

[0321] Another aspect of the invention includes the use of peptides complexed with MHC to generate T cell receptors, the nucleic acid of which is cloned and introduced into a host cell, preferably a T cell. The genetically engineered T cell can then be transferred to a patient for cancer treatment.

[0322] Any molecule of the present invention (i.e., peptide, nucleic acid, antibody, expression vector, cell, activated T cell, T cell receptor or encoding nucleic acid) is beneficial for treating diseases, and its characteristic is that the cell escapes the attack of immune response. Therefore, any molecule of the present invention can be used as a medicament or used to manufacture a medicament. Such a molecule can be used alone or in combination with other molecules of the present invention or known molecules.

[0323] The present invention also relates to a kit comprising:

[0324] (a) a container comprising the pharmaceutical composition in the form of a solution or lyophilized powder;

[0325] (b) an optional second container containing a diluent or reconstitution solution for the lyophilized dosage form; and

[0326] (c) optionally, instructions for use of (i) a solution or (ii) a reconstituted and / or lyophilized formulation.

[0327] The kit further comprises one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe. The container is preferably a bottle, a vial, a syringe or a test tube, and may be a multi-purpose container. The pharmaceutical composition is preferably lyophilized.

[0328] The kit of the present invention preferably comprises a lyophilized formulation placed in a suitable container and instructions for reconstitution and / or use. Suitable containers include, for example, bottles, vials (such as dual chamber bottles), syringes (such as dual chamber syringes) and test tubes. The container may be made of a variety of materials, such as glass or plastic. The kit and / or container preferably has instructions on or about the container indicating directions for reconstitution and / or use. For example, the label may indicate that the lyophilized dosage form will be reconstituted into the above-mentioned peptide concentration. The label may further indicate that the formulation is for subcutaneous injection.

[0329] The container for storing the preparation may be a multi-use vial, so that the reconstituted dosage form can be administered repeatedly (eg, 2-6 times). The kit may further include a second container containing a suitable diluent (eg, sodium bicarbonate solution).

[0330] After the diluent and the lyophilized formulation are mixed, the final peptide concentration in the reconstituted formulation is preferably at least 0.15 mg / mL / peptide (=75 μg) and no more than 3 mg / mL / peptide (=1500 μg). The kit may also include other materials desirable from a commercial and user perspective, including other buffers, diluents, filtrates, needles, syringes, and package inserts with instructions for use.

[0331] The kit of the present invention may have a single container containing the pharmaceutical composition preparation of the present invention, which may have other ingredients (eg, other compounds or pharmaceutical compositions thereof), or no other ingredients, or each ingredient may have its own different container.

[0332] Preferably, the kit of the invention comprises a formulation of the invention packaged for use in combination with a second compound such as an adjuvant (e.g., GM-CSF), a chemotherapeutic drug, a natural product, a hormone or antagonist, an anti-angiogenic agent or inhibitor, an apoptosis inducer or a chelating agent, or a pharmaceutical combination thereof. The components of the kit may be pre-complexed or each component may be placed in a separate container prior to administration to the patient. The components of the kit may be one or more solutions, preferably aqueous solutions, more preferably sterile aqueous solutions. The components of the kit may also be in solid form, converted to liquids upon addition of a suitable solvent, preferably placed in another separate container.

[0333] The container of the treatment kit may be a vial, test tube, flask, bottle, syringe, or any other tool for holding solids or liquids. Typically, when there is more than one ingredient, the kit will contain a second vial or other container so that it can be quantified separately. The kit may also contain another container for loading a medicinal liquid. Preferably, the treatment kit will contain a device (e.g., one or more needles, syringes, eye droppers, pipettes, etc.) that allows the injection of the drug of the present invention (the composition of the present kit).

[0334] The pharmaceutical formulation of the present invention is suitable for peptide administration by any acceptable route, such as oral (enteral), intranasal, intraocular, subcutaneous, intradermal, intramuscular, intravenous or transdermal administration. Preferably, it is administered subcutaneously, most preferably intradermally, and it can also be administered via an infusion pump.

[0335] Since the peptide of the present invention is isolated from lung cancer (including NSCLC and SCLC), the agent of the present invention is preferably used for treating lung cancer (including NSCLC and SCLC).

[0336] The present invention further relates to a method for preparing a personalized medicine for an individual patient, comprising: manufacturing a pharmaceutical composition comprising at least one peptide selected from a pre-screened TUMAP library, wherein the at least one peptide used in the pharmaceutical composition is selected to be suitable for the individual patient. In one embodiment, the pharmaceutical composition is a vaccine. The method can also be modified to produce T cell clones for downstream applications, such as: TCR isolates or soluble antibodies and other therapeutic options.

[0337] “Personalized medicine” refers to treatments that are tailored to an individual patient and will be used only for that individual patient, including personalized active cancer vaccines and adoptive cell therapy using autologous tissue.

[0338] As used herein, a "repository" shall refer to a group or series of peptides that have been pre-screened for immunogenicity and / or are over-presented in a specific tumor type. The term "repository" does not imply that the specific peptides included in the vaccine have been pre-manufactured and stored in a physical device, although this possibility is expected. It is clearly expected that the peptides can be used to newly manufacture each personalized vaccine, and may also be pre-manufactured and stored. The repository (e.g., in the form of a library) consists of tumor-associated peptides that are highly over-expressed in tumor tissues of patients with various HLA-A HLA-B and HLA-C alleles of lung cancer (including NSCLC and SCLC). It may contain MHC class I and MHC class II peptides or elongated MHC class I peptides. In addition to tumor-associated peptides collected from several lung cancer (including NSCLC and SCLC) tissues, the repository may also contain HLA-A*02, HLA-A*01, HLA-A*03, HLA-A*24, HLA-B*07, HLA-B*08 and HLA-A*24B*44 marker peptides. These peptides allow for a quantitative comparison of T cell immunity induced by TUMAPs, allowing important conclusions to be drawn about the ability of the vaccine to respond against tumors. Secondly, they serve as important positive control peptides from "non-self" antigens when no vaccine-induced T cell responses are observed with TUMAPs derived from the patient's "self" antigens. Thirdly, it also allows conclusions to be drawn about the patient's immune function status.

[0339] The repository's TUMAPs were identified using a functional genomics approach that combines gene expression analysis, mass spectrometry, and T cell immunology. This approach ensures that only TUMAPs that are truly present in a high percentage of tumors but are not expressed or only expressed in very low amounts in normal tissues are selected for further analysis. For the initial peptide selection, patient lung cancer (including NSCLC and SCLC) samples and blood from healthy donors were analyzed in a step-by-step approach:

[0340] 1. Determination of HLA ligands of malignant material by mass spectrometry

[0341] 2. Whole genome messenger RNA (mRNA) expression analysis was used to identify genes that are overexpressed in malignant tumor tissues (lung cancer (including NSCLC and SCLC)) compared with a range of normal organs and tissues.

[0342] 3. Comparison of the identified HLA ligands with the gene expression data. Peptides that are overexpressed or selectively presented on tumor tissues, preferably those encoded by the selectively expressed or overexpressed genes detected in step 2, are considered to be suitable candidate TUMAPs for polypeptide vaccines.

[0343] 4. Literature search to identify additional evidence to support the relevance of the peptide identified as TUMP

[0344] 5. The relevance of overexpression at the mRNA level is determined by re-profiling of the TUMAPs selected in step 3 on tumor tissues and the lack (or infrequent) detection on healthy tissues.

[0345] 6. To evaluate whether it is feasible to induce T cell responses in vivo by the selected peptides, in vitro immunogenicity assays were performed using human T cells from healthy donors and patients with lung cancer (including NSCLC and SCLC).

[0346] In one aspect, the peptides are screened for immunogenicity before being added to the repository. For example, but not limited to, the immunogenicity of the peptides included in the repository is determined by in vitro T cell priming, specifically, repeated stimulation of CD8+ T cells from healthy donors with artificial antigen presenting cells loaded with peptide / MHC complexes and anti-CD28 antibodies.

[0347] This approach is preferred for rare cancers and patients with rare expression profiles. In contrast to the peptide cocktails currently developed as fixed components, the library allows a higher degree of matching of the actual expression of antigens in the tumor to the vaccine. In a multi-target approach, each patient will use a selected single peptide or a combination of several "off-the-shelf" peptides. Theoretically, an approach based on the selection of, for example, 5 different antigenic peptides from a library of 50 antigenic peptides could provide approximately 1.7 million possible drug product (DP) components.

[0348] In one aspect, the peptides are selected for use in a vaccine based on suitability for an individual patient and using the methods of the invention as described herein or hereinafter.

[0349] HLA phenotype, transcriptional and peptidomic profiles are collected from patient tumor material and blood samples to identify peptides that are most appropriate for each patient and contain both the "reservoir" and patient-unique (i.e., mutation) TUMAPs. Those peptides selected will be selectively or overexpressed in the patient's tumor and, where possible, demonstrate strong in vitro immunogenicity when tested with the patient's individual PBMCs.

[0350] Preferably, a method for determining the peptides included in the vaccine comprises: (a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from an individual patient; (b) comparing the peptides identified in (a) with a repository (database) of the peptides; and (c) selecting at least one peptide from the repository (database) associated with the tumor-associated peptides identified in the patient. For example, the method for identifying TUMAPs presented by a tumor sample comprises: (a1) comparing the expression data from the tumor sample with the expression data of a normal tissue sample corresponding to the tissue type of the tumor sample to identify proteins overexpressed or abnormally expressed in the tumor tissue; and (a2) correlating the expression data with the sequence of MHC ligands bound to class I MHC and / or class II molecules in the tumor sample to determine the MHC ligands derived from proteins overexpressed or abnormally expressed by the tumor. Preferably, the sequence of the MHC ligand is determined by eluting the MHC molecule-bound peptides separated from the tumor sample and sequencing the eluted ligands. Preferably, the tumor sample and the normal tissue are obtained from the same patient.

[0351] In addition to or as an alternative to using a repository (database) model to select peptides, TUMAPs may be identified in new patients and then included in vaccines. As an example, candidate TUMAPs in patients may be identified by: (a1) comparing expression data from a tumor sample with expression data from a normal tissue sample corresponding to the tissue type of the tumor sample to identify proteins that are overexpressed or abnormally expressed in the tumor tissue; and (a2) correlating the expression data with the sequence of MHC ligands that bind to class I MHC and / or class II molecules in the tumor sample to determine the MHC ligands derived from proteins that are overexpressed or abnormally expressed by the tumor. As another example, the protein identification method may include mutations that are unique to the tumor sample relative to the corresponding normal tissue of the individual patient, and the TUMAP may be identified by specifically targeting the mutation. For example, the genome of the tumor and the corresponding normal tissue may be sequenced by a whole genome sequencing method: in order to discover non-synonymous mutations in the protein coding region of the gene, genomic DNA and RNA are extracted from the tumor tissue, and normal non-mutated genomic germline DNA is extracted from peripheral blood mononuclear cells (PBMC). The NGS method used is limited to the resequencing of protein coding regions (exome resequencing). For this purpose, a target sequence enrichment kit provided by the supplier is used to capture exon DNA from human samples, followed by sequencing using HiSeq2000 (Illumina). In addition, the mRNA of the tumor is sequenced to directly quantify gene expression and confirm that the mutant gene is expressed in the patient's tumor. The millions of sequence reads obtained are processed by software algorithms. The output list includes mutations and gene expression. Tumor-specific somatic mutations are determined and optimized by comparing with PBMC-derived germline changes. Then, the newly determined peptides may be tested for immunogenicity as described above for the library, and candidate TUMAPs with suitable immunogenicity are selected for vaccines.

[0352] In one exemplary embodiment, the peptides included in the vaccine are identified by the following method: (a) identifying tumor-associated peptides (TUMAP) presented by a tumor sample from an individual patient using the above method; (b) comparing the peptides identified in (a) with a library of peptides pre-screened for immunogenicity and over-presentation in tumors (compared to corresponding normal tissues); (c) selecting at least one peptide from the library that is related to the tumor-associated peptides identified in the patient; and (d) optionally selecting at least one newly identified peptide in (a) and confirming its immunogenicity.

[0353] In one exemplary embodiment, the peptides included in the vaccine are identified by: (a) identifying tumor-associated peptides (TUMAPs) presented by tumor samples from individual patients; and (b) selecting at least one newly identified peptide in (a) and confirming its immunogenicity.

[0354] Once the peptides for the personalized peptide vaccine are selected, the vaccine is produced. The vaccine is preferably a liquid formulation comprising the individual peptides dissolved in between 20-40% DMSO, preferably about 30-35% DMSO, for example about 33% DMSO.

[0355] Each peptide included in the product is dissolved in DMSO. The choice of the concentration of the single peptide solution depends on the number of peptides to be included in the product. The single peptide-DMSO solutions are mixed equally to achieve a solution containing all peptides at a concentration of ~2.5 mg / ml per peptide. The mixed solution is then diluted with water for injection at a ratio of 1:3 to achieve a concentration of 0.826 mg / ml per peptide in 33% DMSO. The diluted solution is filtered through a 0.22μm sterile filter. The final bulk solution is obtained.

[0356] The final bulk solution was filled into vials and stored at -20°C before use. One vial contained 700 μL of solution, containing 0.578 mg of each peptide, of which 500 μL (about 400 μg of each peptide) would be used for intradermal injection.

[0357] In addition to being used to treat cancer, the peptides of the present invention can also be used for diagnosis. Since the peptides are produced by lung cancer (including NSCLC and SCLC) cells and it has been determined that these peptides are absent or at low levels in normal tissues, these peptides can be used to diagnose the presence or absence of cancer.

[0358] Tissue biopsies in blood samples containing the claimed peptides can help pathologists diagnose cancer. Detection of certain peptides using antibodies, mass spectrometry or other methods known in the art can enable pathologists to determine whether the tissue sample is malignant or inflammatory or general disease, and can also be used as biomarkers for lung cancer (including NSCLC and SCLC). The presentation of peptide groups allows the classification or further subdivision of diseased tissues.

[0359] Detection of peptides in disease specimens allows the benefit of immune system therapeutic approaches to be determined, especially if T-lymphocytes are known or expected to be involved in the mechanism of action. Loss of MHC expression is a well-characterized mechanism by which infected malignant cells escape immune surveillance. Therefore, presentation of peptides indicates that the analyzed cells do not utilize this mechanism.

[0360] The peptides of the present invention can be used to analyze lymphocyte responses to peptides (such as T cell responses), or antibody responses to peptides or peptides complexed with MHC molecules. These lymphocyte responses can be used as prognostic indicators to determine whether further treatment should be taken. These responses can also be used as alternative response indicators in immunotherapy, which aims to induce lymphocyte responses in different ways, such as protein vaccines, nucleic acids, autologous materials, and adoptive transfer of lymphocytes. In gene therapy, the response of lymphocytes to peptides can be considered in the assessment of side effects. Lymphocyte response monitoring may also become a valuable tool in follow-up examinations of transplantation therapy, such as for detecting graft-versus-host and host-versus-graft diseases.

[0361] The present invention will be described in the following embodiments which describe preferred embodiments, and with reference to (but not limited to) the accompanying drawings. For the purposes of the present invention, all references cited herein are incorporated herein by reference.

[0362] chart

[0363] Figures 1A to 1N Over-representation of various peptides in different cancer tissues is shown (black dots). Upper part: The median MS signal intensity according to technical replicate measurements is plotted as dots, single positive normal tissues are gray dots, and tumor samples where the peptide was detected are black dots. Tumor and normal samples are grouped according to organ of origin, and the box-whisker plot represents the median, 25th and 75th percentiles (boxes) and minimum and maximum values ​​(whiskers) of the normalized signal intensity of multiple samples. Normal organs are ranked according to risk category (blood cells, blood vessels, brain, liver, lung: high risk, gray dots; reproductive organs, breast, prostate: low risk, gray dots; all other organs: medium risk; gray dots). Lower part: The relative frequency of peptide detection in each organ is shown as a spine plot. The numbers below the graph indicate the number of samples where the peptide was detected out of the total number of samples analyzed for each organ. If a peptide was detected on a sample but could not be quantified for technical reasons, the sample was included in the detection frequency plot, but no point was shown in the upper part of the graph. Figures 1A to 1B Over-presentation of various peptides in HLA-A*24 cancer tissues compared to a panel of HLA-A*24 normal samples is shown (normal samples N=19, tumor samples N=94). Tissues (from left to right): Normal samples: bloodvess (blood vessels); brain; heart; liver; lung; kidney; pituitary (pituitary gland). Tumor samples: GBM: glioblastoma; GC: gastric cancer; HCC: hepatocellular carcinoma; NSCLC Cadeno (non-small cell lung cancer adenocarcinoma); NSCLC other (non-small cell carcinoma); NSCLC squam (squamous cell non-small cell lung cancer); SCLC: small cell lung cancer. Figure 1A )Gene symbol: URB1, peptide: LYQEILAQL (SEQ ID NO.: 62), Figure 1B ) Gene symbol: CKAP5, peptide: VYPASKMFPFI (SEQ ID NO.: 65). Figures 1C to 1D Shown are the over-presentation of various peptides in HLA-A*02 cancer tissues compared to a panel of HLA-A*02 normal samples (normal samples N=469, tumor samples N=528). Tissues (from left to right): Normal samples: blood cells; bloodvess (blood vessels); brain; heart; liver; lung; adipose (adipose tissue); adren.gl. (adrenal glands); bile duct; bladder; BM (bone marrow); esoph (esophagus); eye; gallb (gall bladder); head and neck; kidney; large_int (large intestine); LN (lymph node); nerve; pancreas; parathyr (parathyroid gland); perit (peritoneum); pituit (pituitary gland); pleura; skel.mus (skeletal muscle); skin; small_int (small intestine); spleen; stomach; thyroid; trachea; ureter; breast; ovary; placenta; prostate; testis; thymus; uterus. Tumor samples: AML: acute myeloid leukemia; BRCA: breast cancer; CCC: cholangiocarcinoma; CLL: chronic lymphocytic leukemia; CRC: colorectal cancer; GBC: gallbladder cancer; GBM: glioma; GC: gastric cancer; GEJC: gastric cardia-esophageal cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck cancer; MEL: melanoma; NHL: non-Hodgkin's lymphoma; NSCLCadeno (non-small cell lung cancer adenocarcinoma); NSCLCother (non-small cell carcinoma); NSCLCsquam (squamous cell non-small cell lung cancer); OC: ovarian cancer; OSCAR: esophageal cancer; PACA: pancreatic cancer; PRCA: prostate cancer; RCC: renal cell carcinoma; SCLC: small cell lung cancer; UBC: bladder cancer; UEC: uterine and endometrial cancer. Figure 1C )Gene symbol: BMS1, peptide: VLYDKDAVYV (SEQ ID NO.: 129), Figure 1D ) Gene symbol: GORASP2, peptide: NLWGGQGLLGV (SEQ ID NO.: 130). Figures 1E to 1F Over-presentation of various peptides in HLA-A*01 cancer tissues compared to a panel of HLA-A*01 normal samples (normal samples N=13, tumor samples N=40). Tissues (from left to right): Normal samples: blood cells; brain; heart; liver; lung. Tumor samples: GBM: glioblastoma; HCC: hepatocellular carcinoma; NSCLC adeno (non-small cell lung cancer adenocarcinoma); NSCLC other (non-small cell carcinoma); NSCLC squam (squamous cell non-small cell lung cancer); SCLC: small cell lung cancer. Figure 1E)Gene symbol: ZNF439, peptide: LLDISQKNLY (SEQ ID NO: 154), Figure 1F ) Gene symbol: MMP12, peptide: SADDIRGIQSLY (SEQ ID NO.: 174). Figures 1G to 1H Over-presentation of various peptides in HLA-A*03 cancer tissues compared to a panel of HLA-A*03 normal samples (normal samples N=12, tumor samples N=28). Tissues (from left to right): Normal samples: blood cells; bloodvess; brain; heart; liver; lung. Tumor samples: GBM: glioma; GC: gastric cancer; NHL: non-Hodgkin's lymphoma; NSCLCadeno (non-small cell lung cancer adenocarcinoma); NSCLCother (non-small cell carcinoma); NSCLCsquam (squamous cell non-small cell lung cancer); SCLC: small cell lung cancer. Figure 1G )Gene symbol: KRT81, KRT121P, KRT83, KRT85, KRT86, peptide: KLAELEGALQK (SEQ ID NO: 202), Figure 1H ) Gene symbol: NDC80, peptide: SINKPTSER (SEQ ID NO.: 457). Figures 1I to 1J Over-presentation of various peptides in HLA-B*07 cancer tissues compared to a panel of HLA-B*07 normal samples (normal samples N=13, tumor samples N=36). Tissues (from left to right): Normal samples: blood cells; bloodvess (blood vessels); brain; heart; liver; lung. Tumor samples: GBM: glioblastoma; NSCLC Cadeno (non-small cell lung cancer adenocarcinoma); NSCLC other (non-small cell carcinoma); NSCLC squam (squamous cell non-small cell lung cancer); OC: ovarian cancer; SCLC: small cell lung cancer. Fig. 1I )Gene symbol: CTHRC1, peptide: SPQRLRGLL (SEQ ID NO.: 291), Figure 1J ) Gene symbol: MANEA, peptide: RPHKPGLYL (SEQ ID NO.: 475). Figures 1K to 1L Over-presentation of various peptides in HLA-B*08 cancer tissues compared to a panel of HLA-B*08 normal samples is shown (normal sample N=1, tumor sample N=22). Tissues (from left to right): Normal sample: lung. Tumor sample: GBM: glioblastoma; NSCLC adeno (non-small cell lung cancer adenocarcinoma); NSCLC other (non-small cell carcinoma); NSCLC squam (squamous cell non-small cell lung cancer); SCLC: small cell lung cancer. Figure 1K )Gene symbol: VPS13B, peptide: DIYQRALNL (SEQ ID NO.: 315), Figure 1L ) Gene symbol: ARID4A, peptide: LVKVKVLL (SEQ ID NO.: 317). Figures 1M to 1N Over-presentation of various peptides in HLA-B*44 cancer tissues compared to a panel of HLA-B*44 normal samples is shown (normal samples N=15, tumor samples N=25). Tissues (from left to right): Normal samples: brain; heart; liver; lung. Tumor samples: GBM: glioblastoma; NSCLC adeno (non-small cell lung cancer adenocarcinoma); NSCLC other (non-small cell carcinoma); NSCLC squam (squamous cell non-small cell lung cancer); SCLC: small cell lung cancer. Figure 1M )Gene symbol: NUP155, peptide: SEKGVIQVY (SEQ ID NO.: 362), Figure 1N ) Gene symbol: CLSPN, peptide: SEIGKAVGF (SEQ ID NO.: 489).

[0364] Figures 2A to 2N Representative exon expression signatures of source genes of the present invention are shown, which are overexpressed in different cancer samples. Tumor (black dots) and normal (grey dots) samples are grouped according to organ origin, and the box-whisker plots represent the median, 25th and 75th percentiles (boxes) and minimum and maximum (whiskers) RPKM values. Normal organs are ranked according to risk categories. FPKM = fragments per kilobase per million mapped reads. Normal samples: blood cells; bloodvess: blood cap; brain; heart; liver; lung; fat: adipose tissue; adren.gl.: adrenal gland; bile duct; bladder; BM: bone marrow; cartilage; esoph: esophagus; eye; gallb: gallbladder; head and neck; kidney; large_int: large intestine; LN: lymph node; nerve; pancreas; parathyr: parathyroid gland; perit: peritoneum; pituitary gland; pleura; skel.mus: skeletal muscle; skin; small_int: small intestine; spleen; stomach; thyroid gland; trachea; ureter; breast; ovary; placenta; prostate; testis; thymus; uterus. Tumor samples: AML: acute myeloid leukemia; BRCA: breast cancer; CCC: cholangiocarcinoma; CLL: chronic lymphocytic leukemia; CRC: colorectal cancer; GBC: gallbladder cancer; GBM: glioma; GC: gastric cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck cancer; MEL: melanoma; NHL: non-Hodgkin's lymphoma; NSCLCadeno: non-small cell lung cancer adenocarcinoma; NSCLCother: non-small cell lung cancer; NSCLCsquam: non-small cell lung cancer squamous cell; OC: ovarian cancer; OSCAR: esophageal cancer; PACA: pancreatic cancer; PRCA: prostate cancer; RCC: renal cell carcinoma; SCLC: small cell lung cancer; UBC: bladder cancer; UEC: uterine and endometrial cancer. Figure 2A )Gene symbol: ADAMTS12, peptide: QYDPTPLTW (SEQ ID No.: 1), Figure 2B )Gene symbol: MMP12, peptide: VWSNVTPLKF (SEQ ID No.: 2), Figure 2C )Gene symbol: MMP12, peptide: YVDINTFRL (SEQ ID No.: 84), Figure 2D )Gene symbol: KIF26B, peptide: TLYPYQISQL (SEQ ID No.: 87), Figure 2E )Gene symbol: CT83, peptide: NTDNNLAVY (SEQ ID No.: 164), Figure 2F )Gene symbol: LAMA1, peptide: VSDSECLSRY (SEQ ID No.: 189), Figure 2G )Gene symbol: KIF26B, peptide: KVKDTPGLGK (SEQ ID No.: 203), Figure 2H )Gene symbol: SP6, peptide: SLDGAARPK (SEQ ID No.: 205), Fig.2I )Gene symbol: PRAME, peptide: SPSVSQLSVL (SEQ ID No.: 220), Figure 2J )Gene symbol: MMP1, peptide: NPFYPEVEL (SEQ ID No.: 222), Figure 2K )Gene symbol: NLRP2, peptide: FNKRKPLSL (SEQ ID No.: 298), Figure 2L )Gene symbol: KIF26B, peptide: VASPKHCVL (SEQ ID No.: 300), Figure 2M )Gene symbol: MAGEA3, MAGEA6, peptide: MEVDPIGHVYIF (SEQ ID No.: 320), Figure 2N ) Gene symbol: MMP12, peptide: QEMQHFLGL (SEQ ID No.: 326).

[0365] Figure 3Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-A*02+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-A*02 coated artificial APCs, respectively, with SeqID No 520 peptide (KIQEMQHFL, Seq ID NO: 520) (A, left panel). After 3 cycles of stimulation, peptide-reactive cells were detected using 2D multimer staining of A*02 / SeqID No 520 (A). The right panel (B) shows control staining of cells stimulated with irrelevant A*02 / peptide complexes. Live single cells were gated for CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0366] Figure 4 Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-A*24+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-A*24 coated artificial APCs with SeqID No 504 peptide (A, left panel). After 3 cycles of stimulation, peptide-reactive cells were detected using 2D multimer staining of A*24 / SeqID No 504 (VYEKNGYIYF, Seq ID NO: 504) (A). The right panel (B) shows control staining of cells stimulated with an irrelevant A*24 / peptide complex. Live single cells were gated for CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0367] Figure 5 Exemplary results of peptide-specific CD8+ T cell responses in vitro from healthy HLA-A*01+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-A*01 coated artificial APCs synthesized with SeqID No 153 peptide (KLDRSVFTAY, Seq ID NO: 153) (A, left panel) and SeqID No 173 peptide (RTEFNLNQY, Seq ID NO: 173) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining with A*01 / SeqID No 153 (A) or A*01 / SeqID No 173. The right panels (A and B) show control staining of cells stimulated with irrelevant A*01 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0368] Figure 6 Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-A*02+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-A*02 coated artificial APCs synthesized with SeqID No 89 peptide (ILSTTMVTV, Seq ID NO: 89) (A, left panel) and SeqID No 88 peptide (VQMVITEAQKV, Seq ID NO: 88) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining with A*02 / SeqID No 89 (A) or A*02 / SeqID No 88 (B). The right panels (A and B) show control staining of cells stimulated with irrelevant A*02 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0369] Figure 7 Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-A*03+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-A*03 coated artificial APCs treated with SeqID No 208 peptide (GLASRILDAK, Seq ID NO: 208) (A, left panel) and SeqID No 210 peptide (ATSGVPVYK, Seq ID NO: 210) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining of A*03 / SeqID No 208 (A) or A*03 / SeqID No 210 (B). The right panels (A and B) show control staining of cells stimulated with irrelevant A*03 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0370] Figure 8Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-A*24+ donors are shown. CD8+ T cells were prepared by treating artificial APCs coated with anti-CD28 mAb and HLA-A*24 with SeqID No 15 peptide (KYALLLQDL, Seq ID NO: 15) (A, left panel) and SeqID No 11 peptide (YYSKSVGFMQW, Seq ID NO: 11) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining with A*24 / SeqID No 15 (A) or A*24 / SeqID No 11 (B). The right panels (A and B) show control staining of cells stimulated with irrelevant A*24 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0371] Fig. 9 Exemplary results of peptide-specific CD8+ T cell responses in vitro from healthy HLA-B*07+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-B*07 coated artificial APCs treated with SeqID No 225 peptide (LPFDGPGGIL, Seq ID NO: 225) (A, left panel) and SeqID No 248 peptide (IPNWARQDL, Seq ID NO: 248) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining with B*07 / SeqID No 225 (A) or B*07 / SeqID No 248 (B). The right panels (A and B) show control staining of cells stimulated with irrelevant B*07 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0372] Fig.10Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-B*08+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-B*08 coated artificial APCs treated with SeqID No 299 peptide (MAQFKEISL, Seq ID NO: 299) (A, left panel) and SeqID No 297 peptide (RAQLKLVAL, Seq ID NO: 297) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining with B*08 / SeqID No 299 (A) or B*08 / SeqID No 297 (B). The right panels (A and B) show control staining of cells stimulated with irrelevant B*08 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.

[0373] Fig.11 Exemplary results of peptide-specific CD8+ T cell in vitro responses from healthy HLA-B*44+ donors are shown. CD8+ T cells were prepared by treating artificial APCs coated with anti-CD28 mAb and HLA-B*44 with SeqID No 325 peptide (QEQDVDLVQKY, Seq ID NO: 325) (A, left panel) and SeqID No 331 peptide (EDAQGHIW, Seq ID NO: 331) (B, left panel), respectively. After 3 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining, and single cells were gated on CD8+ lymphocytes using B*44 / SeqID No 325 (A) or B*44 / SeqID No 331 (B). The right panels (A and B) show control staining of cells stimulated with irrelevant B*44 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated. Example

[0374] Example 1

[0375] Identification and quantification of tumor-associated peptides presented on the cell surface

[0376] Tissue samples

[0377] Tumor tissues from patients were obtained from: Asterand (Detroit, Michigan, USA & Royston, Hertfordshire, UK), Bio-Options Inc. (Brea, California, USA), Geneticist Inc. (Glendale, California, USA), Heidelberg University Hospital (Heidelberg, Germany), ProteoGenex Inc. (Culver City, California, USA), Tissue Solutions Ltd (Glasgow, UK), and Munich University Hospital (Munich, Germany). Normal tissues were obtained from Asterand (Detroit, Michigan, USA & Royston, Hertfordshire, UK), BioCat GmbH (Heidelberg, Germany), Bio-Options Inc. (Brea, California, USA), Bio-Options Inc. (Brea, California, USA), BioServe (Beltsville, Maryland, USA), Capital BioScience Inc. (Rockville, Maryland, USA), Center for Clinical Transfusion Medicine Tübingen (Tübingen, Germany), Geneticist Inc. (Glendale, California, USA), Kyoto Prefectural University of Medicine (KPUM) (Kyoto, Japan), Osaka City University (OCU) (Osaka, Japan), ProteoGenex Inc. (Culver City, California, USA), Tissue Solutions Ltd (Glasgow, UK), Geneva University Hospital (Geneva, Switzerland), Heidelberg University Hospital (Heidelberg, Germany), Tübingen University Hospital (Tübingen, Germany), Munich University Hospital (Munich, Germany). Written informed consent was obtained from all patients before surgery or autopsy. Tissues were snap-frozen immediately after resection and stored at -70°C or below before TUMAP isolation.

[0378] Isolation of HLA peptides from tissue samples

[0379] The HLA-A*02-specific antibodies BB7.2, HLA-A, HLA-B, HLA- HLA peptide libraries from snap-frozen tissue samples of solid tissues were obtained by immunoprecipitation using the HLA-specific antibody W6 / 32, the HLA-DR-specific antibody L243, and the HLA DP-specific antibody B7 / 21, CNBr-activated agarose gel, acid treatment, and ultrafiltration.

[0380] Mass spectrometry analysis

[0381] The obtained HLA peptide library was separated according to its hydrophobicity by reverse phase chromatography (nanoAcquity UPLC system, Waters), and the eluted peptides were analyzed by LTQ-velos fusion hybrid mass spectrometer (ThermoElectron) equipped with an electrospray source. The peptide library was directly loaded into an analytical fused silica microcapillary column (75 μm inner diameter x 250 mm) packed with 1.7 μm C18 reverse phase material (Waters) with a flow rate of 400 nL / min. Subsequently, the peptides were separated using a two-step 180-min binary gradient from 10% to 33% solvent B at a flow rate of 300 nL / min. The gradient consisted of solvent A (water with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic acid). Gold-coated glass capillaries (PicoTip, New Objective) were used for introduction into the nano-electrospray source. The LTQ-Orbitrap mass spectrometer was operated in data-dependent mode using a top 5 (TOP5) strategy. Briefly, a scan cycle was started with a full scan in orbitrap with high quality accuracy (R=30000), followed by MS / MS scans of the five most abundant precursor ions in orbitrap (R=7500) with dynamic exclusion of previously selected ions. Tandem mass spectra were interpreted by SEQUEST with a fixed false discovery rate (q≤≤0.05) and additional manual controls. In cases where the determined peptide sequence was uncertain, the peptide sequence was further verified by comparing the fragmentation pattern of the generated natural peptide with that of a synthetic sequence-identical reference peptide.

[0382] Label-free relative LC-MS quantification was performed by ion counting (i.e., by LC-MS feature extraction and analysis) (Mueller et al., 2007). This approach assumes that the LC-MS signal area of ​​a peptide is related to its abundance in the sample. The extracted features were further processed by charge state deconvolution and retention time alignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MS features were cross-referenced with sequence identification results to combine quantitative data from different samples and tissues with peptide presentation features. Quantitative data were normalized in a two-layered manner based on the pooled data to account for technical and biological replicate variations. Therefore, each identified peptide could be associated with quantitative data, allowing relative quantification between samples and tissues. In addition, all quantitative data obtained for candidate peptides were manually checked to ensure data consistency and to verify the accuracy of the automated analysis. For each peptide, a presentation plot was calculated, which shows sample mean presentation as well as replicate variation. These features juxtapose the baseline values ​​of cancer samples with those of normal tissue samples. The presentation profiles of exemplary over- or exclusively presented peptides on tumors are shown in FIG1 .

[0383] Table 8 shows the presentation of selected peptides in various cancer entities, thus indicating the particular relevance of the mentioned peptides for diagnosis and / or treatment of the indicated cancers (eg: hepatocellular carcinoma for peptide SEQ ID No. 3, melanoma, ovarian cancer and uterine cancer for peptide SEQ ID No. 11).

[0384] Table 8: Summary of selected tumor-associated peptides of the present invention presented in various entities. AML = acute myeloid leukemia, BRCA = breast cancer, CCC = bile duct cancer, GBM = brain cancer, CLL = chronic lymphocytic leukemia, CRC = colorectal cancer, OSCAR = esophageal cancer, GBC = gallbladder adenocarcinoma, GC = gastric cancer, HNSCC = head and neck squamous cell carcinoma, HCC = hepatocellular carcinoma, MEL = melanoma, NHL = non-Hodgkin's lymphoma, OC = ovarian cancer, PACA = pancreatic cancer, PRCA = prostate cancer and benign prostatic hyperplasia, RCC = renal cell carcinoma, UBC = bladder cancer, UEC = uterine cancer.

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401] Example 2

[0402] Expression profile of the gene encoding the peptide of the present invention

[0403] Over- or specific presentation of a peptide on tumor cells compared to normal cells is sufficient for its effective use in immunotherapy, and some peptides are tumor-specific despite the presence of their source protein also present in normal tissues. However, mRNA expression profiles add an additional level of safety in the selection of immunotherapy target peptides. Especially for treatment options with high safety risks, such as affinity-matured TCRs, the ideal target peptide will be derived from a protein that is unique to the tumor and not present in normal tissues.

[0404] RNA source and preparation

[0405] Surgical resection tissue specimens were provided as described above (see Example 1) after written informed consent was obtained from each patient. Tumor tissue specimens were snap-frozen immediately after surgery and then homogenized in liquid nitrogen with a pestle and mortar. Total RNA was prepared from these samples using TRI reagent (Ambion, Darmstadt, Germany) followed by RNeasy (QIAGEN, Hilden, Germany) cleanup; both methods were performed according to the manufacturer's protocol.

[0406] Total RNA from healthy human tissues for RNASeq experiments was obtained from: Asterand (Detroit, MI, USA & Royston, Hertfordshire, UK), Bio-Options Inc. (Brea, CA, USA), BioCat GmbH (Heidelberg, Germany), (Beltsville, MD, USA), Geneticist Inc. (Glendale, CA, USA), Heidelberg University Hospital (Thoraxklinik, Heidelberg, Germany), Istituto Nazionale Tumori "Pascale" (Naples, Italy), ProteoGenex Inc. (Culver City, CA, USA).

[0407] Total RNA from tumor tissues for RNASeq experiments was obtained from: Asterand (Detroit, MI, USA & Royston, Hertfordshire, UK), Geneticist Inc. (Glendale, CA, USA), ProteoGenex Inc. (Culver City, CA, USA), Tissue Solutions Ltd (Glasgow, UK), University Hospital Bonn (Bonn, Germany), University Hospital Tübingen (Tübingen, Germany).

[0408] The quality and quantity of all RNA samples were assessed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).

[0409] RNAseq experiments

[0410] Gene expression analysis of RNA samples from tumors and normal tissues was performed by CeGaT (Tübingen, Germany) using next-generation sequencing (RNAseq). Briefly, sequencing libraries were prepared using the Illumina HiSeq v4 kit according to the supplier's protocol (Illumina Inc., San Diego, CA, USA), which included RNA fragmentation, cDNA conversion, and addition of sequencing adapters. Libraries obtained from multiple samples were mixed equimolarly according to the manufacturer's instructions and sequenced on an Illumina HiSeq2500 sequencer, generating 50 bp single-end reads. The processed reads were mapped to the human genome (GRCh38) using STAR software. Expression data were set at the transcript level as RPKM (reads per kilobase per million mapped reads, generated by Cufflinks software) and at the exon level (total reads, generated by Bedtools software) according to the instructions of the ENSEMBL sequence database (Ensembl77). Exonic reads were normalized to exon length and size calibration to obtain RPKM values.

[0411] The expression profiles of representative source genes of the present invention that are highly overexpressed in lung cancer (including NSCLC and SCLC) are shown in Figure 2. The expression scores of further representative genes are shown in Table 9.

[0412] Table 9: Expression scores. This table lists peptides from genes that are very highly overexpressed (+++) in lung cancer tissues (NSCLCCadeno = non-small cell lung cancer adenocarcinoma; NSCLCsquam = non-small cell lung cancer squamous cell; NSCLCother = non-small cell lung cancer, other subtypes; SCLC = small cell lung cancer) compared to a range of normal tissues, highly overexpressed on tumors compared to a range of normal tissues (++), or overexpressed on tumors compared to a range of normal tissues (+). This baseline score was calculated based on measurements of the following relevant normal tissues: adipose tissue, adrenal glands, bile ducts, blood cells, blood vessels, bone marrow, brain, cartilage, esophagus, eyes, gallbladder, heart, head and neck, kidneys, large intestine, liver, lungs, lymph nodes, nerves, parathyroid glands, pancreas, pituitary gland, pleura, skeletal muscle, skin, small intestine, spleen, stomach, thyroid gland, trachea, bladder, ureters. If expression data were obtained for several samples of the same tissue type, the arithmetic mean of each sample was used for calculation.

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423] Example 3

[0424] In vitro immunogenicity of MHC class I presented peptides

[0425] In order to obtain information about the immunogenicity of the TUMAPs of the invention, the inventors performed studies using an in vitro T cell expansion assay based on repeated stimulation with artificial antigen presenting cells (aAPCs) loaded with peptide / MHC complexes and anti-CD28 antibodies. Using this method, the inventors could show that the HLA-A*02:01, HLA-A*24:02, HLA-A*01:01, HLA-A*03:01, HLA-B*07:02, HLA-B*08:01 and HLA-B*44:02 restricted TUMAPs of the invention are immunogenic, indicating that these peptides are T cell epitopes against human CD8+ precursor T cells (Tables 10a and 10b).

[0426] In vitro priming of CD8+ T cells

[0427] For in vitro stimulation with artificial antigen-presenting cells loaded with peptide-MHC complexes (pMHC) and anti-CD28 antibodies, the inventors first isolated CD8+ T cells from healthy donors obtained from the University clinics Mannheim (University clinics Mannheim) using CD8 microbeads (Miltenyi Biotec, Bergis Gladbach, Germany) by positive selection of fresh HLA-A*02, HLA-A*24, HLA-A*01, HLA-A*03, HLA-B*07, HLA-B*08 or HLA-B*44 products after leukapheresis.

[0428] PBMC and isolated CD8+ lymphocytes were cultured in T cell medium (TCM) before use, which included RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat-inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U / ml penicillin / 100 μg / ml streptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro, Oberdorla, Germany) and 20 μg / ml gentamicin (Cambrex). At this step, 2.5 ng / ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U / ml IL-2 (Novartis Pharma, Nuremberg, Germany) were also added to TCM.

[0429] Generation of pMHC / anti-CD28 coated beads, stimulation of T cells and readout were performed in a highly defined in vitro system using four different pMHC molecules per stimulation condition and 8 different pMHC molecules per readout condition.

[0430] Purified co-stimulatory mouse IgG2a anti-human CD28 antibody 9.3 (Jung et al., 1987) was chemically biotinylated using N-hydroxysuccinimide biotin as recommended by the manufacturer (Perbio, Bonn, Germany). The beads used were 5.6 μm streptavidin-coated polystyrene particles (Bangs Laboratories, Illinois, USA).

[0431] The pMHC used for positive and negative control stimuli were A*02:01 / MLA-001 (peptide ELAGIGILTV (SEQ ID NO. 532) modified from Melan-A / MART-1) and A*02:01 / DDX5-001 (YLLPAIVHI (SEQ ID NO. 533) obtained from DDX5), respectively.

[0432] 800.000 beads / 200 μl were coated in a 96-well plate containing 4 x 12.5 ng of different biotin-pMHC, washed, and then 600 ng of biotin anti-CD28 in a volume of 200 μl was added. Stimulation was initiated by co-culturing 1 x 106 CD8+ T cells with 2 x 105 washed coated beads in 200 μtl TCM containing 5 ng / ml IL-12 (PromoCell) at 37°C for 3 days. Afterwards, half of the culture medium was exchanged with fresh TCM supplemented with 80 U / ml IL-2, and the culture was continued at 37°C for 4 days. This stimulation cycle was performed 3 times in total. For pMHC multimer readout using 8 different pMHC molecules per condition, the 2D combinatorial encoding method was used as previously described (Andersen et al., 2012), with slight modifications to cover coupling to 5 different fluorescent dyes. Finally, multimer analysis was performed using Live / dead near IR dye (Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD, Heidelberg, Germany) and fluorescent pMHC multimers. For the analysis, a BD LSRII SORP cytometer equipped with an appropriate laser and screening program was used. Peptide-specific cells were calculated as a percentage of total CD8+ cells. The results of the multimer analysis were evaluated using FlowJo software (Tree Star, OR, USA). In vitro loading of specific multimer+CD8+ lymphocytes was tested by comparison with negative control stimulation groups. The immunogenicity of a given antigen was tested if at least one evaluable in vitro stimulated well in a healthy donor was found to contain a specific CD8+ T cell line after in vitro stimulation (i.e., the well contained at least 1% specific multimer+CD8+ T cells and the percentage of specific multimer+ was at least 10 times the median of the negative control stimulation).

[0433] In vitro immunogenicity of lung cancer (including NSCLC and SCLC) peptides

[0434] For the tested HLA-I class peptides, their in vitro immunogenicity can be demonstrated by the generation of peptide-specific T cell lines. Typical results of flow cytometry detection after staining of the 16 peptides of the present invention with TUMAP-specific multimers are shown in Figure 1. Figures 3 to 11 The results of the 152 peptides of the present invention are summarized in Table 10a and Table 10b.

[0435] Table 10a: In vitro immunogenicity of HLA class I peptides of the present invention

[0436] Exemplary results of in vitro immunogenicity experiments conducted by the applicant on the peptides of the present invention. <20% = +; 20%-49% = ++; 50%-69% = +++; > = 70% = ++++

[0437]

[0438]

[0439] Table 10b: In vitro immunogenicity of HLA class I peptides of the present invention

[0440] Exemplary results of in vitro immunogenicity experiments conducted by the applicant on the peptides of the present invention. <20% = +; 20%-49% = ++; 50%-69% = +++; > = 70% = ++++

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447] Example 4

[0448] Peptide synthesis

[0449] All peptides were synthesized by standard, well-established solid phase peptide synthesis using the Fmoc strategy. The identity and purity of each peptide was confirmed using mass spectrometry and RP-HPLC analysis. Lyophilization (trifluoroacetate) yielded white to off-white peptides with a purity of >50%. All TUMAPs are preferably administered as trifluoroacetate or acetate salts, although other pharmaceutically acceptable salt forms are also possible.

[0450] Example 5

[0451] MHC binding assay

[0452] The candidate peptides for T cell therapy of the present invention are further tested for their MHC binding ability (affinity). Single peptide-MHC complexes are generated by UV-ligand exchange, wherein the UV-sensitive peptide is cleaved after UV irradiation and exchanged with the relevant peptides analyzed. Only candidate peptides that can effectively bind and stabilize the peptide-receiving MHC molecules can prevent the dissociation of the MHC complex. In order to determine the yield of the exchange reaction, an ELISA assay is performed based on the detection results of the light chain (β2m) of the stable MHC complex. The detection is generally carried out according to the method described by Rodenko et al. in (Rodenko et al., 2006).

[0453] 96-well Maxisorp plates (NUNC) were coated with 2ug / ml streptavidin in PBS at room temperature overnight, washed 4 times and blocked in 2% BSA in blocking buffer at 37°C for 1 hour. Folded HLA-A*02:01 / MLA-001 monomers were used as standards, covering the range of 15-500ng / ml. Peptide-MHC monomers for UV exchange reactions were diluted 100-fold in blocking buffer. Samples were incubated at 37°C for 1 hour, washed four times, incubated with 2ug / ml HRP-conjugated anti-β2m at 37°C for 1 hour, washed again, and detected with TMB solution blocked with NH2SO4. Absorption was measured at 450nm. When generating and producing antibodies or fragments thereof and / or T cell receptors or fragments thereof, candidate peptides that show high exchange yields (preferably above 50%, most preferably above 75%) are generally preferred because they show sufficient affinity for MHC molecules and can prevent the dissociation of the MHC complex.

[0454] Table 11: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-A*01 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0455]

[0456]

[0457]

[0458]

[0459] Table 12: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-A*02 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0460]

[0461]

[0462]

[0463] Table 13: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-A*03 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0464]

[0465] Table 14: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-A*24 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0466]

[0467]

[0468]

[0469]

[0470] Table 15: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-B*07 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0471]

[0472]

[0473]

[0474] Table 16: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-B*08 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0475]

[0476]

[0477] Table 17: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-B*44 is divided into ranges according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++

[0478]

[0479]

[0480]

[0481] The present invention includes but is not limited to the following items:

[0482] 1. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 489, and variant sequences thereof having at least 88% homology with SEQ ID No. 1 to SEQ ID No. 489, wherein the variant binds to the major histocompatibility complex (MHC) and / or induces T cell cross-reaction with the variant peptide, and a pharmaceutically acceptable salt thereof, wherein the peptide is not a full-length polypeptide.

[0483] 2. The peptide according to item 1, wherein the peptide is capable of binding to MHC class I or -II molecules, wherein the peptide can be recognized by CD4 and / or CD8 T cells when bound to MHC.

[0484] 3. The peptide or variant thereof according to item 1 or 2, wherein the amino acid sequence comprises a continuous stretch of amino acids of any of SEQ ID No. 1 to SEQ ID No. 489.

[0485] 4. A peptide or variant thereof according to any one of items 1 to 3, wherein the total length of the peptide or variant thereof is 8 to 100 amino acids, preferably 8 to 30 amino acids, more preferably 8 to 16 amino acids, and most preferably the peptide consists of or essentially consists of an amino acid sequence according to any SEQ ID No.1 to SEQ ID No.489.

[0486] 5. The peptide or variant thereof according to any one of items 1 to 4, wherein the peptide is modified and / or comprises non-peptide bonds.

[0487] 6. A peptide or variant thereof according to any one of items 1 to 5, wherein the peptide is part of a fusion protein, in particular comprising the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

[0488] 7. An antibody, particularly a soluble or membrane-bound antibody, preferably a monoclonal antibody or a fragment thereof, which specifically recognizes a peptide or a variant thereof according to any one of items 1 to 5, and when bound to an MHC molecule, is preferably a peptide or a variant according to any one of items 1 to 5.

[0489] 8. A T cell receptor, preferably a soluble or membrane-bound receptor or a fragment thereof, which reacts with an HLA ligand, wherein the ligand is a peptide or variant thereof according to any one of items 1 to 5, and when bound to an MHC molecule, it is preferably a peptide or variant according to any one of items 1 to 5.

[0490] 9. A T cell receptor according to item 8, wherein the ligand amino acid sequence is at least 88% identical to any one of SEQ ID No. 1 to SEQ ID No. 489, or wherein the ligand amino acid sequence comprises any one of SEQ ID No. 1 to SEQ ID No. 489.

[0491] 10. A T cell receptor according to any one of items 8 or 9, wherein the T cell receptor is provided as a soluble molecule and optionally has further effector functions, such as an immunostimulatory domain or a toxin.

[0492] 11. An aptamer that specifically recognizes the peptide or variant thereof according to items 1 to 5, preferably the peptide or variant according to any one of items 1 to 5 that binds to an MHC molecule.

[0493] 12. A nucleic acid encoding a peptide or variant thereof according to any one of items 1 to 5, an antibody or fragment thereof according to item 7, a T cell receptor or fragment thereof according to item 8 or 9, optionally linked to a heterologous promoter sequence or an expression vector for expressing said nucleic acid.

[0494] 13. A recombinant host cell comprising a peptide according to any one of items 1 to 6, an antibody or a fragment thereof according to item 7, a T cell receptor or a fragment thereof according to item 8 or 9, or a nucleic acid or an expression vector according to item 12, wherein the host cell is preferably selected from antigen presenting cells, such as dendritic cells, T cells or NK cells.

[0495] 14. A method for preparing activated T lymphocytes in vitro, the method comprising connecting T cells in vitro with human class I or II MHC molecules carrying antigens, which are expressed on the surface of suitable antigen-presenting cells or on the surface of artificially analogous antigen-presenting cell structures for a sufficient period of time to activate T cells in an antigen-specific manner, wherein the antigen is a peptide described in any one of items 1 to 4.

[0496] 15. The activated T lymphocyte prepared according to the method described in Item 14, which selectively recognizes a cell presenting a polypeptide comprising the amino acid sequence given in any one of Items 1 to 4.

[0497] 16. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of a peptide according to any one of items 1 to 6, an antibody or a fragment thereof according to item 7, a T cell receptor or a fragment thereof according to item 8 or 9, an aptamer according to item 11, a nucleic acid or an expression vector according to item 12, a host cell according to item 13, or an activated T lymphocyte according to item 15, or a conjugated or labeled active ingredient and a pharmaceutically acceptable carrier and optionally a pharmaceutically acceptable excipient and / or stabilizer.

[0498] 17. A method for preparing a peptide or variant thereof according to any one of items 1 to 6, an antibody or fragment thereof according to item 7, or a T cell receptor or fragment thereof according to item 8 or 9, the method comprising culturing a host cell according to item 13 and isolating the peptide or variant thereof, the antibody or fragment thereof, or the T cell receptor or fragment thereof from the host cell and / or its culture medium.

[0499] 18. Use of the peptide described in any one of items 1 to 6, the antibody or fragment thereof described in item 7, the T cell receptor or fragment thereof described in item 8 or 9, the aptamer described in item 11, the nucleic acid or expression vector described in item 12, the host cell described in item 13 or the activated T lymphocyte described in item 15 in medicine.

[0500] 19. A method for killing targeted cells in a patient, wherein the targeted cells present a polypeptide comprising the amino acid sequence given in any one of items 1 to 4; a method of administration, comprising administering to the patient an effective amount of T cells as defined in item 15.

[0501] 20. Use of the peptide described in any one of items 1 to 6, the antibody or fragment thereof described in item 7, the T cell receptor or fragment thereof described in item 8 or 9, the aptamer described in item 11, the nucleic acid or expression vector described in item 12, the host cell described in item 13 or the activated T lymphocyte described in item 15 in cancer diagnosis and / or treatment or in the manufacture of anti-cancer drugs.

[0502] 21. The use according to claim 20, wherein the cancer is selected from the group consisting of lung cancer (including NSCLC and SCLC), acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, bladder cancer, uterine cancer and other tumors that show overexpression of a peptide derived from a protein according to SEQ ID No. 1 to SEQ ID No. 489.

[0503] 22. A kit comprising:

[0504] a) A container comprising a pharmaceutical composition, the pharmaceutical composition comprising the peptide according to any one of items 1 to 6, the antibody or fragment thereof according to item 7, the T cell receptor or fragment thereof according to item 8 or 9, the aptamer according to item 11, the nucleic acid or expression vector according to item 12, the host cell according to item 13, or the activated T lymphocyte in solution or lyophilized form according to item 15.

[0505] b) optionally, a second container containing a diluent or reconstitution solution for the lyophilized powder dosage form;

[0506] c) optionally at least one peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 531, and

[0507] d) optionally, instructions for (i) using the solution or (ii) reconstitution and / or use of the lyophilized dosage form.

[0508] 23. The kit of claim 22, further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.

[0509] 24. A method for producing a personalized anti-cancer vaccine or compound-based and / or cell therapy for use as an individual patient, the method comprising:

[0510] a) identifying tumor-associated peptides (TUMAPs) presented by tumor samples from said individual patient;

[0511] b) comparing the peptides identified in a) with peptides from a library that have been pre-screened for immunogenicity and / or are over-presented in tumors compared to normal tissues.

[0512] c) selecting at least one peptide in the repository that matches a TUMAP identified in the patient; and

[0513] d) producing and / or conceiving said personalized vaccine or compound-based and / or cell therapy based on step c).

[0514] 25. The method according to item 24, wherein the TUMAP is identified by:

[0515] a1) comparing the expression profile of the tumor sample with the expression profile of a normal tissue sample corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or abnormally expressed in the tumor sample; and

[0516] a2) Correlating the expression profiles with the sequences of MHC ligands bound by MHC class I and / or class II molecules in tumor samples to identify MHC ligands derived from proteins that are overexpressed or aberrantly expressed by the tumor.

[0517] 26. The method according to item 24 or 25, wherein the sequence of the MHC ligand is determined by eluting the MHC molecule-bound peptides isolated from the tumor sample and sequencing the eluted ligand.

[0518] 27. The method according to any one of items 24 to 26, wherein the normal tissue sample corresponding to the tumor sample of the same type is obtained from the same patient.

[0519] 28. The method according to any one of items 24 to 27, wherein the peptides contained in the storage library are identified based on the following steps: aa. performing genome-wide messenger RNA (mRNA) expression analysis by highly parallel methods, such as microarray or sequencing-based expression profiling, which includes identifying genes that are overexpressed in malignant tissue compared to normal tissue;

[0520] ab. selecting a peptide encoded by a gene that is specifically expressed or overexpressed as detected in step aa, and

[0521] ac. Determining the induction of an in vivo T cell response by a selected peptide, including an in vitro immunogenicity assay using human T cells from a healthy donor or said patient; or

[0522] ba. identifying HLA ligands from the tumor sample by mass spectrometry;

[0523] bb. Genome-wide messenger RNA (mRNA) expression analysis by highly parallel methods, such as microarray or sequencing-based expression profiling, including identification of genes overexpressed in malignant tissue compared to normal tissue;

[0524] bc. Comparison of the identified HLA ligands with the gene expression profile;

[0525] bd. a peptide encoded by a gene specifically expressed or overexpressed detected in step bc;

[0526] be. re-detecting the selected TUMAP from step bd on tumor tissue, which is absent or infrequently detected on healthy tissue, and determining the relevance of overexpression at the mRNA level;

[0527] as well as

[0528] bf. Determination of in vivo T cell responses induced by selected peptides, including in vitro immunogenicity assays using human T cells from healthy donors or said patients.

[0529] 29. A method according to any one of items 24 to 28, wherein whether the repository includes peptide immunogenicity is determined by a method comprising in vitro immunogenicity experiments, individual HLA binding patient immune monitoring, MHC multimer staining, ELISPOT analysis and / or intracellular cytokine staining.

[0530] 30. The method according to any one of items 24 to 29, wherein the storage library comprises a plurality of peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 531.

[0531] 31. The method according to any one of items 24 to 30, further comprising the following steps:

[0532] At least one mutation that is unique to the tumor sample compared to corresponding normal tissue from the individual patient is identified, and a peptide associated with the mutation is selected for inclusion in a vaccine or for use in the production of a cell therapy.

[0533] 32. A method according to claim 31, wherein at least one mutation is identified using whole genome sequencing.

[0534] References

[0535] Allison,JPet al.,Science 270(1995):932-933

[0536] Andersen,RSet al.,Nat.Protoc.7(2012):891-902

[0537] Appay, V. et al., Eur. J Immunol. 36 (2006): 1805-1814

[0538] Banchereau,J.et al.,Cell 106(2001):271-274

[0539] Beatty,G.et al.,J Immunol 166(2001):2276-2282

[0540] Beggs,JD,Nature 275(1978):104-109

[0541] Benjamini,Y.et al.,Journal of the Royal Statistical Society.SeriesB(Methodological),Vol.57(1995):289-300

[0542] Boulter,JMet al.,Protein Eng 16(2003):707-711

[0543] Braumuller,H.et al.,Nature(2013)

[0544] Brossart,P.et al.,Blood 90(1997):1594-1599

[0545] Bruckdorfer,T.et al.,Curr.Pharm.Biotechnol.5(2004):29-43

[0546] Card,KFet al.,Cancer Immun Immunother.53(2004):345-357

[0547] Cohen,CJet al.,J Mol Recognit.16(2003a):324-332

[0548] Cohen,CJet al.,J Immunol 170(2003b):4349-4361

[0549] Cohen,SNet al.,Proc.Natl.Acad.Sci.USA69(1972):2110-2114

[0550] Coligan,JEet al.,Current Protocols in Protein Science(1995)

[0551] Colombetti,S.et al.,J Immunol.176(2006):2730-2738

[0552] Dengjel,J.et al.,Clin Cancer Res 12(2006):4163-4170

[0553] Denkberg,G.et al.,J Immunol 171(2003):2197-2207

[0554] Falk,K.et al.,Nature 351(1991):290-296

[0555] Follenzi,A.et al.,Night Genet.25(2000):217-222

[0556] Fong,L.et al.,Proc.Natl.Acad.Sci.USA98(2001):8809-8814

[0557] Gabrilovich,DIet al.,Night Med.2(1996):1096-1103

[0558] Gattinoni,L.et al.,Nat Rev.Immunol 6(2006):383-393

[0559] Gnjatic,S.et al.,Proc Natl.Acad.Sci.U.S.A100(2003):8862-8867

[0560] Godkin,A.et al.,Int.Immunol 9(1997):905-911

[0561] Gragert,L.et al.,Hum.Immunol.74(2013):1313-1320

[0562] Green,M.R.et al.,Molecular Cloning,A Laboratory Manual 4th(2012)

[0563] Greenfield,E.A.,Antibodies:A Laboratory Manual 2nd(2014)

[0564] Gustafsson,C.et al.,Trends Biotechnol.22(2004):346-353

[0565] Hwang,M.L.et al.,J Immunol.179(2007):5829-5838

[0566] Jung,G.et al.,Proc Natl Acad Sci U S A 84(1987):4611-4615

[0567] Kibbe,A.H.,Handbook of Pharmaceutical Excipients rd(2000)

[0568] Krieg,A.M.,Nat Rev.Drug Discov.5(2006):471-484

[0569] Kuball,J.et al.,Blood 109(2007):2331-2338

[0570] Liddy,N.et al.,Nat Med.18(2012):980-987

[0571] Ljunggren,H.G.et al.,J Exp.Med.162(1985):1745-1759

[0572] Longenecker,B.M.et al.,Ann N.Y.Acad.Sci.690(1993):276-291

[0573] Lonsdale,J.,Nat.Genet.45(2013):580-585

[0574] Lukas,T.J.et al.,Proc.Natl.Acad.Sci.U.S.A 78(1981):2791-2795

[0575] Lundblad,R.L.,Chemical Reagents for Protein Modification 3rd(2004)

[0576] Meziere,C.et al.,J Immunol 159(1997):3230-3237

[0577] Morgan,R.A.et al.,Science 314(2006):126-129

[0578] Mortara,L.et al.,Clin Cancer Res.12(2006):3435-3443

[0579] Mueller,L.N.et al.,J Proteome.Res 7(2008):51-61

[0580] Mueller,L.N.et al.,Proteomics.7(2007):3470-3480

[0581] Mumberg,D.et al.,Proc.Natl.Acad.Sci.U.S.A 96(1999):8633-8638

[0582] Pinheiro,J.et al.,nlme:Linear and Nonlinear Mixed Effects Models(http: / / CRAN.R-project.org / packe=nlme)(2015)

[0583] Plebanski,M.et al.,Eur.J Immunol 25(1995):1783-1787

[0584] Porta,C.et al.,Virology 202(1994):949-955

[0585] Rammensee,H.et al.,Immunogenetics 50(1999):213-219

[0586] Reinmuth,N.et al.,Dutch.Med.Wochenschr.140(2015):329-3

[0587] Rini,BIet al.,Cancer 107(2006):67-74

[0588] Rock,KLet al.,Science 249(1990):918-921

[0589] Rodenko,B.et al.,Nat Protoc.1(2006):1120-1132

[0590] S3-Lung Line Carcinoma,020 / 007,(2011)

[0591] Saiki,RKet al.,Science 239(1988):487-491

[0592] Schmitt,TMet al.,Hum.Gene Ther.20(2009):1240-1248

[0593] Scholten,KBet al.,Clin Immunol.119(2006):135-145

[0594] Seeger,FHet al.,Immunogenetics 49(1999):571-576

[0595] SEER Stat Facts,(2014),http: / / seer.cancer.gov /

[0596] J Clin.Oncol.31(2013):2173-2181

[0597] Sherman,F.et al.,Laboratory Course Manual for Methods inYeastGenetics(1986)

[0598] Singh-Jasuja,H.et al.,Cancer Immunol.Immunother.53(2004):187-195

[0599] Small,E.J.et al.,J Clin Oncol.24(2006):3089-3094

[0600] Sturm,M.et al.,BMC.Bioinformatics.9(2008):163

[0601] Teufel,R.et al.,Cell Mol Life Sci.62(2005):1755-1762

[0602] Tran,E.et al.,Science 344(2014):641-645

[0603] Travis,W.D.et al.,J Clin.Oncol.31(2013):992-1001

[0604] Walter,S.et al.,J Immunol 171(2003):4974-4978

[0605] Walter,S.et al.,Nat Med.18(2012):1254-1261

[0606] Willcox,B.E.et al.,Protein Sci.8(1999):2418-2423

[0607] World Cancer Report,(2014)

[0608] Zaremba,S.et al.,Cancer Res.57(1997):4570-4577

[0609] Zufferey,R.et al.,J Virol.73(1999):2886-2892

Claims

1. A peptide or a pharmaceutically acceptable salt thereof, the peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 405, 1 to 219, 221 to 404, and 406 to 489, wherein the total length of the peptide is 8 to 16 amino acids.

2. A nucleic acid encoding the peptide according to claim 1.

3. A recombinant host cell comprising the peptide according to claim 1 or the nucleic acid according to claim 2.

4. A method for preparing the peptide according to claim 1, the method comprising: Cultivating the recombinant host cell according to claim 3, and isolating the peptide from the recombinant host cell or the culture medium of the recombinant host cell.

5. A method for preparing activated T lymphocytes in vitro, the method comprising contacting T cells with human class I or class II MHC molecules loaded with antigens for a period of time sufficient to activate the T cells in an antigen-specific manner, wherein the human class I or class II MHC molecules are expressed on the surface of a suitable antigen-presenting cell or on the surface of an artificial structure that simulates an antigen-presenting cell, wherein the antigen is the peptide according to claim 1.

6. The activated T lymphocyte prepared by the method according to claim 5, wherein the activated T lymphocyte selectively recognizes cells presenting the peptide according to claim 1.

7. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of the peptide or pharmaceutically acceptable salt thereof according to claim 1, the nucleic acid according to claim 2, the recombinant host cell according to claim 3, or the activated T lymphocyte according to claim 6.

8. Use of the peptide or pharmaceutically acceptable salt thereof according to claim 1, the nucleic acid according to claim 2, the recombinant host cell according to claim 3 or the activated T lymphocyte according to claim 6 in the preparation of a medicament for diagnosing, preventing and / or treating cancer.

9. A kit comprising: (a) a container comprising a pharmaceutical composition in a solution or lyophilized form, wherein the pharmaceutical composition comprises the peptide or a pharmaceutically acceptable salt thereof according to claim 1, the nucleic acid according to claim 2, the recombinant host cell according to claim 3, or the activated T lymphocyte according to claim 6; (b) optionally, a second container comprising a diluent or reconstitution solution for the lyophilized dosage form; (c) optionally, at least one other peptide selected from SEQ ID NOs: 1 to 404 and 406 to 531, and (d) optionally, one or more of (i) a buffer, (ii) a diluent, (iii) a filter, (iv) a needle, (v) a syringe, or (vi) an adjuvant.

10. An in vitro method for providing data for diagnosing cancer in a sample, the sample comprising cells from a subject, the method comprising: (a) adding antibodies or T cell receptors to a tissue sample of the subject, and (b) detecting the binding of the antibody or the T cell receptor to cells from the tissue sample of the subject, thereby identifying the presentation of the tumor-associated peptide of claim 1 on cells from the tissue sample of the subject, wherein the antibody or T cell receptor specifically recognizes (i) the peptide according to claim 1 or (ii) the peptide when bound to an MHC molecule.